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[57] ABSTRACT 
A novel class of peptide a-ketoamides useful for selectively 
inhibiting serine proteases, selectively inhibiting cysteine 
proteases, generally inhibiting all serine proteases, and gen-
erally inhibiting all cysteine proteases, having the formula 
Y-CO-AA 2-AA 1-CO- NH-X. Processes for the 
synthesis of peptidyl a-ketoamide derivatives. 




This is a continuation-in-part of application Ser. No. 
07/948,454 filed on Sep. 21, 1992 now abandoned. 
2 
erence]. An amino acid residue (AA) in a peptide or inhibitor 
structure refers to the part structure -NH-CHR1-CO-, 
where R1 is the side chain of the amino acid residue AA. A 
peptide a-ketoester residue would be designated -AA-
BACKGROUND OF THE INVENTION 
FIELD OF THE INVENTION 
5 CO-OR which represents the part structure -NH-
CHR1-CO-CO-OR. Thus, the ethyl ketoester derived 
from benzoyl alanine would be designated Bz-Ala-CO-OEt 
which represents C6H5CO-NH-CHMe-CO- CO-OEt. 
Likewise, peptide ketoacid residues and peptide ketoamide 
10 residues would be designated -AA-CO-OH and 
-AA-CO-NH-R respectively. Thus, the ethyl keto 
amide derived from Z-Leu-Phe-OH would be designated 
Z-Leu-Phe-CO-NH-Et which represents C6H5CH20CO-
NH-CH(CH2CHMez)-CO-NH-CH(CH2Ph)-CO-
This invention relates to a novel class of peptidyl a-ke-
toamides useful for selectively inhibiting serine proteases, 
selectively inhibiting cysteine proteases, generally inhibit-
ing all serine proteases, and generally inhibiting all cysteine 
proteases. Serine proteases and cysteine proteases are 
involved in numerous disease states and inhibitors for these 
enzymes can be used therapeutically for the treatment of 
diseases involving serine proteases or cysteine proteases. We 
have discovered that peptidyl a-ketoamides can be con-
structed to inhibit selectively individual serine or cysteine 
proteases or groups of serine or cysteine proteases. We have 20 
found that peptidyl ketoamides which contain hydrophobic 
aromatic amino acid residues in the P 1 site are potent 
inhibitors of chymases and chymotrypsin-like enzymes. 
Ketoamides containing small hydrophobic amino acid resi-
dues at the P 1 position are good inhibitors of elastases. 25 
Inhibitors of elastases and chymases are useful as anti-
inflammatory agents. We have found that peptide ketoam-
ides which contain cationic amino acid residues such as Arg 
and Lys in the P 1 site are potent inhibitors of trypsin and 
blood coagulation enzymes. These inhibitors are thus useful 30 
as anticoagulants. Ketoamides with aromatic amino acid 
residues in the P 1 site would be good inhibitors for cysteine 
proteases such as papain, cathepsin B, and calpain I and IL 
Thus, they would have utility as anticancer agents. Ketoa-
rnides with either aromatic amino acid residues or small 35 
hydrophobic alkyl amino acid residues at P 1 are good 
inhibitors of calpain I and IL Ketoamides with small alkyl 
amino acid residues such as Leu or Val at P 2 are also good 
inhibitors of the calpains. We have found that ketoamides 
which have both a hydrogen bonding group such as 40 
hydroxyl or alkoxy and an aromatic group are more effective 
inhibitors for calpain I, calpain II, cathepsin B and human 
neutrophil elastase. Ketoamides which contain a heterocylic 
group also are more potent inhibitors for calpain I, calpain 
15 CO-NH-Et. 
DESCRIPTION OF THE RELATED ART 
Serine Proteases 
Serine proteases play critical roles in several physiologi-
cal processes such as digestion, blood coagulation, comple-
ment activation, fibrinolysis, viral infection, fertilization, 
and reproduction. Serine proteases are not only a physi-
ological necessity, but also a potential hazard if they are not 
controlled. Uncontrolled proteolysis by elastases may cause 
pancreatitis, emphysema, rheumatoid arthritis, bronchial 
inflammation and adult respiratory distress syndrome. It has 
been suggested that a new trypsin-like cellular enzyme 
(tryptase) is involved in the infection of human immunode-
ficiency virus type 1 [HIV-1; Hattori et al., FEBS Letters 
248, pp. 48-52 (1989)], which is a causative agent of 
acquired immunodeficiency syndrome (AIDS). Plasrnin is 
involved in tumor invasiveness, tissue remodeling, blister-
ing, and clot dissociation. Accordingly, specific and selec-
tive inhibitors of these proteases should be potent antico-
agulants, anti-inflammtory agents, anti-tumor agents and 
anti-viral agents useful in the treatment of protease-related 
diseases [Powers and Harper, Proteinase Inhibitors, pp. 
55-152, Barrett and Salvesen, eds., Elsevier, (1986); incor-
porated herein by reference]. In vitro proteolysis by chy-
motrypsin, trypsin or the elastase family is a serious problem 
II, cathepsin B and human neutrophil elastase. The ketoa- 45 
rnides which are calpain inhibitors would be useful as 
neuroprotectants and can be used as therapeutics for the 
treatment of neurodegeneration, stroke, restenosis, and 
related diseases. 
in the production, purification, isolation, transport or storage 
of peptides and proteins. Accordingly, inhibitors of serine 
proteases could be useful for the prevention of such undes-
ired proteolysis. 
Elastase inhibitors are anti-inflammatory agents which 
can be used to treat elastase-associated inflammation includ-
ing rheumatoid arthritis and emphysema. Although the natu-
rally occurring protease inhibitor, al-protease inhibitor (al-
Nomenclature 
In discussing the interactions of peptides with serine and 
cysteine proteases, we have utilized the nomenclature of 
Schechter and Berger [Biochem. Biophys. Res. Commun. 27, 
157-162 (1967); incorporated herein by reference]. The 
individual amino acid residues of a substrate or an inhibitor 
are designated P 1, P 2, etc. and the corresponding subsites of 
the enzyme are designated S1, S2, etc. The scissile bond of 
the substrate is Si-S1'. The primary substrate recognition 
site of serine proteases is S 1. The most important recognition 
subsites of cysteine proteases are S1 and S2. With both serine 
and cysteine proteases, there are additional recognition sites 
at the prime subsites such as S1' and S2'. 
Amino acid residues and blocking groups are designated 
using standard abbreviations [see J. Biol. Chem. 260, 14-42 
(1985) for nomenclature rules; incorporated herein by ref-
50 Pl) has been used to treat patients with emphysema, this 
protein inhibitor is not widely used clinically due to the high 
dosage needed for treatment and the difficulty of producing 
large quantities. Therefore small molecular weight elastase 
inhibitors are needed for therapy. Other low molecular 
55 weight elastase inhibitors have utility for the treatment of 
emphysema and inflammation (see: l-carpapenem-3-car-
boxylic esters as anti-inflammatory agents, U.S. Pat. No. 
4,493,839; N-carboxyl-thienamycin esters and analogs 
thereof as anti-inflammatory agents, U.S. Pat. No. 4,495, 
60 197; incorporated herein by reference). 
Anticoagulants and antithrombotic drugs are used in a 
variety of thrombotic disorders. The 1990 Physician's Desk 
Reference lists se_veral anticoagulant drugs (heparin, prota-
mine sulfate and warfarin), a few antiplatelet drugs (aspirin) 
65 and several thrombolytic agents. Heparin and warfarin are 
commonly used clinically for prevention and treatment of 
venous thrombosis and pulmonary embolism. Heparin 
5,514,694 
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inhibits the blood coagulation activity by accelerating the 
binding of natural plasma protease inhibitor antithrombin III 
with coagulation factors, and warfarin acts as a vitamin K 
antagonist and inhibits the synthesis of coaguation factors. 
None of the anticoagulant drugs, antithrombotic drugs, 5 
fibrinolytic agents and antiplatelet drugs are highly effective 
in all clinical situations and many induce side reactions [Von 
Kaulla, Burger's Medicinal Chemistry, Part II, pp 
1081-1132, Wolff, ed., (1979); incorporated herein by ref-
erence]. Coagulation disorders such as disseminated intra- IO 
vascular coagulation, bleeding complications of medical and 
surgical procedures and bleeding complications of systemic 
illness are still difficult to manage [Ingram, Brozovic and 
Slater, Bleeding Disorders, pp 1- 413, Blackwell Scientific 
Publications, (1982); incorporated herein by reference]. In 15 
the treatment of patients with coagulation problems, antico-
agulant or antithrombotic agents of diverse mechanisms are 
urgently sought in order to provide better medical care. 
Inhibitors for the trypsin-like enzymes involved in blood 
coagulation are useful anticoagulants in vivo [see for 20 
example: H-D-Phe-Pro-Arg-CH2Cl, Hanson and Harker, 
Proc. Natl. Acad. Sci. 85, 3184-3188 (1988); 7-Amino-4-
chloro-3-(3-isothiureidopropoxy)isocoumarin (ACIDC), 
Oweida, Ku, Lumsden, Kam, and Powers, Thrombos. Res. 
4 
peptin (Ac-Leu-Leu-Arg-H), as well as epoxysuccinates 
such as E-64. These compounds are not especially useful at 
inhibiting calpain in neural tissue in vivo because they are 
poorly membrane permeant and, accordingly, are not likely 
to cross the blood brain barrier very well. Also, many of 
these inhibitors have poor specificity and will inhibit a wide 
variety of proteases in addition to cal pain. In addition, other 
classes of compounds which inhibit cysteine proteases 
include peptide diazomethyl ketones (Rich, D. H., in Pro-
tease Inhibitors, Barrett A. J., and Salversen, G., Eds., 
Elsevier, N.Y. 1986, pp 153-178; incorporated herein by 
reference). Peptide diazomethyl ketones are potentially car-
cinogenic and are thought to be poorly membrane permeant 
and to have low specificity. Thus, no effective therapy has 
yet been developed for most neurodegenerative diseases and 
conditions. Millions of individuals suffer from neurodegen-
erative diseases and thus, there is a need for therapies 
effective in treating and preventing these diseases and con-
ditions. 
Cathepsin B is involved in muscular dystrophy, myocar-
dial tissue damage, tumor metastasis, and bone resorption. 
In addition, a number of viral processing enzymes, which 
are essential for viral infection, are cysteine proteases. 
Inhibitors of cysteine proteases would thus have multiple 
58, 191-197 (1990); incorporated herein by reference]. 
Cysteine Proteases. 
25 therapeutic uses. 
Cysteine proteases such as calpain use a cysteine residue 
in their catalytic mechanism in contrast to serine proteases 
which utilize a serine residue. Cysteine proteases include 
papain, cathepsin B, calpains, and several viral enzymes. 30 
Neural tissues, including brain, are known to possess a large 
variety of proteases, including at least two calcium stimu-
lated proteases termed calpains. Calpains are present in 
many tissues in addition to the brain. Calpain I is activated 
by micromolar concentrations of calcium while calpain II is 35 
activated by millimolar concentrations. In the brain, calpain 
II is the predominant form, but calpain I is found at synaptic 
endings and is thought to be the form involved in long term 
potentiation, synaptic plasticity, and cell death. Other Ca2+ 
activated cysteine proteases may exist, and the term 40 
"calpain" is used to refer to all Ca2+ activated cysteine 
proteases, including calpain I and calpain II. The terms 
"calpain I" and "calpain II" are used herein to refer to the 
micromolar and millimolar activated calpains, respectively, 
as described above. While calpains degrade a wide variety of 45 
protein substrates, cytoskeletal proteins seem to be particu-
larly susceptible to attack. In some cases, the products of the 
proteolytic digestion of these proteins by calpain are dis-
tinctive and persistent over time. Since cytoskeletal proteins 
are major components of certain types of cells, this provides 50 
a simple method of detecting calpain activity in cells and 
tissues. Thus, calpain activation can be measured indirectly 
Ketoesters. 
A few amino acid and peptide ketoesters and ketoacids 
have been previously reported. Cornforth and Cornforth [J. 
Chem. Soc., 93-96 (1953); incorporated herein by reference] 
report the synthesis of the ketoacids PhCH2CO-Gly-CO-
OH and Ac-Gly-CO-OH upon hydrolysis of heterocyclic 
molecules. Charles et al. [J. Chem. Soc. Perkin I, 1139-1146 
(1980); incorporated herein by reference] use ketoesters for 
the synthesis of bicyclic heterocycles. They report the syn-
thesis of n-Bu-CO-Ala-CO-OEt, Pr-CO-Ala-CO-OEt, 
cyclopentyl-CO-Ala-CO-OEt, Pr-CO-Phg-CO-OEt, and Bz-
Ala-CO-OEt. Hori et al. [Peptides: Structure and Function-
Proceedings of the Ninth American Peptide Symposium 
(Deber, Hruby, and Kopple, Eds.) Pierce Chemical Co., pp 
819-822 (1985); incorporated herein by reference] report 
Bz-Ala-CO-OEt, Bz-Ala-CO-OH, Z-Ala-Ala-Abu-CO-
OEt, Ala-Ala-Abu-CO-OBzl, and Z-Ala-Ala-Ala-Ala-CO-
OEt (Abu=2-arninobutanoic acid or a-arninobutyric acid) 
and report that these compounds inhibit elastase. Trainer 
[Trends Pharrn. Sci. 8, 303-307 (1987); incorporated herein 
by reference] comments on one of this compounds. 
Burkhart, J., Peet, N. P., and Bey, P. [Tetrahedron Lett. 29, 
3433-3436 (1988); incorporated herein by reference] report 
the synthesis of Z-Val-Phe-CO-OMe and Bz-Phe-CO-
OMe. 
Mehdi et al. [Biochem. Biophys. Res. Comm. 166, 
595-600 (1990); incorporated herein by reference] report 
the inhibition of human neutrophil elastase and cathepsin G 
by peptide a-ketoesters. Angelastro et al., [J. Med. Chem. 
33, 13-16 (1990); incorporated herein by reference] report 
some a-ketoesters which are inhibitors of calpain and chy-
motrypsin. Hu and Abeles [Arch. Biochem. Biophys. 281, 
271-274 (1990); incorporated herein by reference] report 
some peptidyl a-ketoarnides and a-ketoacids which are 
inhibitors of cathepsin B and papain. Peet et al. [J. Med. 
Chem. 33,394-407 (1990); incorporated herein by refer-
ence] report some peptidyl a-ketoesters which are inhibitors 
of porcine pancreatic elastase, human neutrophil elastase, 
and rat & human neutrophil cathepsin G. 
by assaying the proteolysis of the cytoskeletal protein spec-
trin, which produces a large, distinctive and biologically 
persistent breakdown product when attacked by calpain 55 
[Siman, Baudry, and Lynch, Proc. Natl. Acad. Sci. USA 81, 
3572-3576 (1984); incorporated herein by reference]. Acti-
vation of calpains and/or accumulation of breakdown prod-
ucts of cytoskeletal elements has been observed in neural 
tissues of mammals exposed to a wide variety of neurode- 60 
generative diseases and conditions. For example, these phe-
nomena have been observed following ischemia in gerbils 
and rats, following stroke in humans, following administra-
tion of the toxins kainate, trimethyltin or colchicine in rats, 
and in human Alzheimer's disease. 65 Ketoarnides. 
Several inhibitors of calpain have been described includ-
ing peptide aldehydes such as Ac-Leu-Leu-Nle-H and leu-
A single peptide ketoarnide is reported in the literature by 
Hu and Abeles [Arch. Biochem. Biophys. 281, 271-274 
5,514,694 
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(1990)]. This compound Z-Phe-NHCH2CO-CO-NH-Et 
or Z-Phe-Gly-CO-NH-Et is reported to be an inhibitor of 
papain (K.r=l.5 mM) and cathepsin B (K_r=4 mM). 
SUMMARY OF THE INVENTION 
5 
6 
available peptide derivatives. These processes should be 
widely applicable to the synthesis of many new a-ketoamide 
derivatives of peptides. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Peptide a-ketoamides are transition state analog inhibi-
tors for serine proteases and cysteine proteases. Peptide 
a-ketoamides containing hydrophobic amino acid residues 
in the P 1 site have been found to be excellent inhibitors of 
serine proteases including porcine pancreatic elastase and 
bovine chymotrypsin. We show that peptide a-ketoamides 
containing amino acid residues with· cationic side chains in 
We have discovered that peptidyl a-ketoamide deriva-
tives are a novel group of inhibitors for serine proteases and 
cysteine proteases. Inhibitors are compounds that reduce or 
eliminate the catalytic activity of the enzyme. We have 
discovered that peptidyl a-ketoamide derivatives, which 10 
have an amino acid sequence similar to that of good sub-
strates for a particular protease, are good inhibitors for that 
protease. Thus, we are able to predict the structure of new 
inhibitors for other serine and cysteine proteases based on 
knowledge of their substrate specificities. 
The peptidyl a-ketoamide derivatives are novel and 
potent inhibitors of cysteine proteases including calpains, 
cathepsin B, and papain. The calpain inhibitors are useful for 
treatment of various neurodegenerative diseases and condi-
tions, including ischemia, stroke, and Alzheimer's disease. 20 
They will also be useful for the treatment of restenosis. 
15 the P 1 site will be excellent inhibitors of several serine 
proteases including bovine trypsin, bovine thrombin, human 
plasma kallikrein, porcine pancreatic kallikrein, human fac-
tor Xia and human plasmin. Peptide a-ketoamides contain-
ing amino acid residues with hydrophobic side chain at the 
We have discovered some peptidyl a-ketoamide deriva-
tives which are specific inhibitors for trypsin, elastase, 
chymotrypsin, granzymes, and other serine proteases, and 
some of the derivatives which are general inhibitors for 25 
groups of serine proteases. Trypsin and trypsin-like enzymes 
normally cleave peptide bonds in proteins and peptides 
where the amino acid residue on the carbonyl side of the 
split bond (P1 residue) is Lys or Arg. Peptide a-ketoamide 
derivatives which have Lys or Arg at P1 are thus good 
30 
inhibitors for these enzymes. Elastase and elastase-like 
enzymes cleave peptide bonds where the P 1 amino acid is 
Ala, Val, Ser, Leu and other similar amino acids. Inhibitors 
with these residues at P 1 are good elastase inhibitors. Chy-
motrypsin and chymotrypsin-like enzymes hydrolyze pep- 35 
tide bonds where P 1 amino acid is Trp, Tyr, Phe, Met, Leu 
or other amino acid residues which contain aromatic or large 
alkyl side chains. Inhibitors with these residues at P1 are 
good chymotrypsin and chymase inhibitors. All of the above 
enzymes have extensive secondary specificity and recognize 40 
amino acid residues removed from the P 1 residue. 
The new protease inhibitors, especially the elastase 
inhibitors, trypsin inhibitors, and chymase inhibitors are 
useful for controlling tissue damage and various inflamma-
tory conditions mediated by proteases such as blistering. The 
45 
inhibitors for blood coagulation enzymes are useful antico-
agulants and could be used to treat thrombosis. 
The peptidyl a-ketoamide derivatives are also useful in 
vitro for inhibiting trypsin, elastase, chymotrypsin and other 50 
serine proteases of similar specificity, and for inhibiting 
serine proteases in general. The inhibitors can be used to 
identify new proteolytic enzymes encountered in research. 
They can also be used in research and industrially to prevent 
undesired proteolysis that occurs during the production, 55 
isolation, purification, transport and storage of valuable 
peptides and proteins. Such proteolysis often destroys or 
alters the activity and/or function of the peptides and pro-
teins. Uses would include the addition of the inhibitors to 
antibodies, enzymes, plasma proteins, tissue extracts or 60 
other proteins and peptides which are widely sold for use in 
clinical analyses, biomedical research, and for many other 
reasons. For some uses a specific inhibitor would be desir-
able, while in other cases, an inhibitor with general speci-
ficity would be preferred. 65 
We have also discovered several new processes for the 
synthesis of a-ketoamide derivatives of peptides from easily 
P 1 site have also been found to be excellent inhibitors of 
several cysteine proteases including papain, cathepsin B, 
calpain I, and calpain II. Inhibitors with a P2 Leu, Val or 
similar residues are particularly good inhibitors for the 
calpains. Addition of a heterocyclic, aromatic, or hydrogen 
bonding group to the amide portion of the inhibitor results 
in improved inhibitory potency and specificity due to inter-
action with S' subsites of the targeted enzyme. 
These structures may be used in vivo to treat diseases such 
as emphysema, adult respiratory distress syndrome, rheu-
matoid arthritis and pancreatitis which result from uncon-
trolled proteolysis by elastase, chymotrypsin, trypsin and 
related serine proteases. These inhibitors may be used in 
vitro to prevent proteolysis which occurs in the process of 
production, isolation, purification, storage or transport of 
peptides and proteins. These inhibitors may be useful as 
therapeutic agents for treatment of neurodegeneration, viral 
infections, muscular dystrophy, myocardial tissue damage, 
tumor metastasis, restenosis, and bone resorption. 
Detailed Description of Peptide a-Ketoamides 
The novel class of dipeptide a-ketoamides have the 
following structural formula: 
Y-CO-AA2-AA1-CO-NH-X 
or a pharmaceutically acceptable salt, wherein 
Y is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, C1_4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxy dis-
ubstituted with phenyl, ArCH20-, ArO-, 
ArCH2NH-, ArNH-, M1-(CH ' - and 2 Vq ' 
M -(CH2)q-O; 
wherein Ar is selected from the group consisting of 
phenyl, phenyl monosubstituted with J, phenyl disub-
stituted with J, 1-naphthyl, 1-naphthyl monosubstituted 
with J, 2-naphthyl, and 2-naphthyl monosubstituted 
with J; 
J is selected from the group consisting of halogen, OH, 
CN, N02 , NH2, COOR, C02Me, C02Et, CF3 , C1_4 
alkoxy, C1_4alkylamine, C2 _8 dialkylamine, C1_4 per-
fiuoroalkyl, and -N(CH2CH2)z0; 
M1 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 
2-pyrazinyl, 2-quinolinyl, 1-tetrahydroquinolinyl, 
5,514,694 
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1-isoquinolinyl, 2 -tetrahydroisoquinolinyl, and 
-N(CH2CH2)zO; 
q==0-2; 
M2 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 2-pyrazinyl, 2-quinolinyl, 5 
2-tetrahydroquinolinyl, 1-isoquinolinyl, and 1-tetrahy-
droisoquinolinyl; 
AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 10 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-CH(CH2- 15 
CHEt2)-COOH, alpha-arninoheptanoic acid, NH2-
CH(CH2-cyclohexyl)-COOH, NH2-CH(CH2-cyclo-
pentyl)-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH2 -CH(CH2-cyclopropyl)-COOH, 5,5,5-
trifiuoroleucine, and hexafiuoroleucine; 20 
AA 1 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, 4-chloropheny-
lalanine valine, leucine, isoleucine, proline, histidine, 
methionine, methionine sulfoxide, phenylalanine, argi- 25 
nine, lysine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, phenylglycine, norleucine, norvaline, 
alpha-arninobutyric acid, 0-methylserine, 0-eth-




CH(CH2 -cyclohexyl)-COOH, NH2 -CH(CH2-
cyclopentyl)-COOH, NH2-CH(CH2-cyclobutyl)- 35 
COOH, NH2-CH(CH2-cyclopropyl)-COOH, 5,5,5-
trifiuoroleucine, and hexafiuoroleucine; 
X is selected from the group consisting of 
a) -CH2CH(OH)-R 1 and 
b) -(CH2)n-R3 ; 
R1 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 








1-naphthyl, 1-naphthyl monosubstituted with J, 
1-naphthyl disubstituted with J, 2-naphthyl, 2-naphthyl 
60 
monosubstituted with J, 2-naphthyl disubstituted with 
J, 2-pyridyl, 2-quinolinyl, and 1-isoquinolinyl; 
R2 represents C1_4 alkyl, C1_4 alkyl substituted with 
phenyl, phenyl and phenyl substituted with J; 
FW; ~ 
R3 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosub-
8 
stituted with J, 3-pyridyl, 3-pyridyl monosubstituted 
with J, 4-pyridyl, 4-pyridyl monosubstituted with J, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 
J, 
(>_ 00 




N N N N 
~ ~ ~ 
0 0 0 
r\-Z~ G 
N , N , N 0, 
I I I 
Me 
0 0 
~Me~ ~ Jl l JL7>-




Me ~I J: JL~>- -4 ~Me 
0 N , N , 
I 
Me 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
M 1CO-AA2-AA 1-CO-NH-CH2CH(OH)-R1 
or a pharmaceutically acceptable salt, wherein 
M 1 is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, C1_4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxy dis-
ubstituted with phenyl, ArCH20--, ArO--, 
ArCH2NH-, and ArNH-; 
wherein Ar is selected from the group consisting of 
phenyl, phenyl monosubstituted with J, phenyl disub-
5,514,694 
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stituted with J, 1-naphthyl, 1-naphthyl monosubstituted 
with J, 2-naphthyl, and 2-naphthyl monosubstituted 
with J; 
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOH, C02Me, C02Et, CF3 , C1_4 5 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fiuoroalkyl, and -N(CH2CH2)20; 
AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 10 
isoleucine, proline, histidine, methionine, methionirie 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-CH(CH2- 15 
CHEt2)-COOH, alpha-aminoheptanoic acid, NH2-
CH(CH2-cyclohexyl)-COOH, NH2-CH(CH2-cyclo-
pentyl)-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH2-CH(CH2 -cyclopropyl)-COOH, 5,5,5-
trifiuoroleucine, and hexafiuoroleucine; 20 
AA 1 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
front the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, arginine, lysine, tryptophan, 25 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, phenylg-
lycine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2- 30 
CH(CH2CHE~)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-
2napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-
COOH, NH2-CH(CH2 -cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, NH2- 35 
CH(CH2-cyclopropyl)-COOH, 5,5,5-trifiuoroleucine, 
and hexafiuoroleucine; 
R1 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 
40 phenyl trisubstituted with J, pentafiuorophenyl, 
1-naphthyl, 1-naphthyl monosubstituted with J, 
1-naphthyl disubstituted with J, 2-naphthyl, 2-naphthyl 
monosubstituted with J, 2-naphthyl disubstituted with 




R2 represents C1_4 alkyl substituted with phenyl, phenyl 60 
and phenyl substituted with J. 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
M 1CO-AA2-AA 1-CO-NH-(CH,)"-R3 
or a pharmaceutically acceptable salt, wherein 
65 
10 
M1 is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, C1_4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxy dis-
ubstituted with phenyl, ArCH20-, ArO-, 
ArCH2NH-, and ArNH-; 
wherein Ar is selected from the group consisting of 
phenyl, phenyl monosubstituted with J, phenyl disub-
stituted with J, 1-naphthyl, 1-naphthyl monosubstituted 
with J, 2-naphthyl, and 2-naphthyl monosubstituted 
with J; 
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOH, C02Me, C02Et, CF3 , C1_4 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fiuoroalkyl, and -N(CH2CH2hO; 
AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-




COOH, 5,5,5-trifiuoroleucine, and hexafiuoroleucine; 
AA 1 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, arginine, lysine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, phenylg-
lycine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHE~)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-
2-napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-





R3 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosub-
stituted with J, 3-pyridyl, 3-pyridyl monosubstituted 
with J, 4-pyridyl, 4-pyridyl monosubstituted with J, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 
J, 
()___ 
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The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
M 3-(CH,).-CO-AA2-AA1-CO-NH-CH2CH(OH)-R1 










M3 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 50 2-pyrazinyl, 2-quinolinyl, 1-tetrahydroquinolinyl, 
1-isoquinolinyl, 2tetrahydroquinolinyl, and 
-N(CH2CH2hO; 
q=0-2; 
AA 2 is an amino acid with the L configuration, D con- 55 
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, praline, histidine, methionine, methionine 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 60 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-cyclohexyl)--COOH, NH2-
CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cy- 65 
clobutyl)--COOH, NH2--CH(CH2 -cyclopropyl)-
COOH, 5,5,5-trifiuoroleucine, and hexafiuoroleucine; 
12 
AA 1 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, praline, histidine, methionine, methionine 
sulfoxide, phenylalanine, arginine, lysine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, phenylg-
lycine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHE~)-COOH, alpha-aminoheptanoic acid, 
NH2--CH(CHr 1-napthyl)--COOH, NH2--CH(CH2-
2-napthyl)--COOH, NH2--CH(CH2-cyclohexyl)-




R1 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, pentafiuorophenyl, 
OR2 
ri -0 u, \ /) OR2, 
1-naphthyl, 1-naphthyl monosubstituted with J, 
1-naphthyl disubstituted with J, 2-naphthyl 2-naphthyl 
monosubstituted with J, 2-naphthyl disubstituted with 
J, 2-pyridyl, 2-quinolinyl, and 1-isoquinolinyl; 
R2 represents C1_4 alkyl substituted with phenyl, phenyl 
and phenyl substituted with J. 
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOR, C02Me, C02Et, CF3 , C1_4 
alkoxy, C1_4 alkylamine, C2_8 dialkylamine, C1_4 per-
fiuoroalkyl, and N(CH2CH2h0; 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
M 3-(CH2).-CO-AA2-AA1-CO-NH-(CH2).-R3 
or a pharmaceutically acceptable salt, wherein 
M3 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 
2-pyrazinyl, 2-quinolinyl, 1-tetrahydroquinolinyl, 
1-isoquinolinyl, 2 -tetrahydroisoquinolinyl, and 
-N(CH2CH2hO; 
q=0-2 
AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, praline, histidine, methionine, methionine 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-






COOH, 5,5,5-trifiuoroleucine, and hexafiuoroleucine; 
AA 1 is an amino acid with the L configuration, D con- 5 
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, arginine, lysine, tryptophan, 10 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, p~enylg­
lycine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
· S-ethylcysteine, S-benzylcysteine, NH2-









R3 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosub-
stituted with J, 3-pyridyl, 3-pyridyl monosubstituted 
with J, 4-pyridyl, 4-pyridyl monosubstituted with J, 30 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 
J, 
n-~ ~N) o I , 
0 0 
~Me~ 
:i Jl l JL7>-














; JL~>- ~ )_Me 
0 N , N , 
I 
Me 
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOR, C02Me, C02Et, CF3, C1_4 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fiuoroalkyl, and N(CH2CH2h0; 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
M4-(CH,)q-O-CO-AA2-AA 1-CO-NH-
CH2CH(OH)-R1 
or a pharmaceutically acceptable salt, wherein 
M4 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 2-pyrazinyl, 2-quinolinyl, 
2-tetrahydroquinolinyl, 1-isoquinolinyl, and 1-tetrahy-
droisoquinolinyl; 
q=0-2; 
AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-




COOH, 5,5,5-trifiuoroleucine, and hexafiuoroleucine; 
AA 1 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, arginine, lysine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutarnine, aspartic acid, glutamic acid, phenylg-
lycine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHE~)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-
2-napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-




R 1 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 





1-naphthyl, 1-naphthyl monosubstituted with J, 15 
1-naphthyl disubstituted with J, 2-naphthyl 2-naphthyl 
monosubstituted with J, 2-naphthyl disubstituted with 
J, 2-pyridyl, 2-quinolinyl, and 1-isoquinolinyl; 
R2 represents C1_4 alkyl substituted with phenyl, phenyl 
and phenyl substituted with J. 20 
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOR, C02Me, C02Et, CF3 , C1_4 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fiuoroalkyl, and N(CH2CH2)z0; 
The novel class of dipeptide a-ketoamides also have the 25 
following structural formula: 
M4 -(CH2)q--O--CO-AA2-AA1-CO-NH-(CH,).-R3 
or a pharmaceutically acceptable salt, wherein 
M4 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 2-pyrazinyl, 2-quinolinyl, 





AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 40 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-




COOH, 5,5,5-trifiuoroleucine, and hexafiuoroleucine; 
AA 1 is an amino acid with the L configuration, D con- 50 
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, arginine, lysine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar- 55 
agine, glutamine, aspartic acid, glutamic acid, phenylg-
lycine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 60 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-
2-napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-
COOH, NH2-CH(CH2 -cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, NH2-




R3 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosub-
stituted with J, 3-pyridyl, 3-pyridyl monosubstituted 
with J, 4-pyridyl, 4-pyridyl monosubstituted with J, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 
J, 
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J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOR, C02Me, C02Et, CF3 , C1_4 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fluoroalkyl, and N(CH2CH2)z0. 
Processes For the Synthesis of a-Ketoamides 
We have also discovered a process for the synthesis of 






M is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, cl-4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxr, dis- 5 
ubstituted with phenyl, Ar1CH20-, Ar 0-, 
Ar1CH2NH-, Ar1NH- and Heterocycle1(CH:z)q-; 
Ar1 is selected from the group consisting of phenyl, 
phenyl monosubstituted with J, phenyl disubstituted 
with J, 1-naphthyl, 1-naphthyl monosubstituted with J, 10 
2-naphthyl, and 2-naphthyl monosubstituted with J; 
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOH, C02Me, C02Et, CF3 , C1_4 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fluoroalkyl, and -N(CH2CH2)i0; 15 
Heterocycle1 is selected from the group consisting of 
2-furyl, 2-tetrahydrofuryl, 2-pyrazinyl, 3-pyridyl, 4-pyridyl, 
2-quinoliny 1, 1-tetrahydroquinolinyl, 1-isoquinoliny 1, 2-tet-
rahydroisoquinolinyl, and -N(CH2CH2)20; 
q=0-2; 20 
AA 1, AA 2 and AA 3 are side chain blocked or unblocked 
a-amino acids with the L configuration, D configura-
tion, or DL configuration at the a-carbon selected 
independently from the group consisting of alanine, 
valine, leucine, isoleucine, histidine, proline, methion- 25 
ine, methionine sulfoxide, phenylalanine, serine, threo-
nine, phenylglycine, norleucine, norvaline, arginine, 
lysine, tryptophan, glycine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, alpha-
aminobutyric acid, 0-methylserine, 0-ethylserine, 30 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEti)-COOH, alpha-aminohep-
tanoic acid, NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-
CH(CH2-cyclobutyl)-COOH, NH2-CH(CH2-cyclo- 35 
propyl)-COOH, NH2-CH(CHr 1-naphthyl)-
COOH, NH2-CH(CH2-2-naphthyl)-COOH, 5,5,5-
trifiuoroleucine, and hexafiuoroleucine; 
R is selected from the group consisting of H, C1_20 alkyl, 40 
cl-20 cyclized alkyl, cl-20 alkyl with a phenyl group 
attached to the cl-20 alkyl, c!-20 cyclized alkyl with an 
attached phenyl group, cl-20 alkyl with an attached 
phenyl group substituted with K, C1_20 alkyl with an 
attached phenyl group disubstituted with K, C1_20 alkyl 45 
with an attached phenyl group trisubstituted with K, 
cl-20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_IO alkyl with a morpholine 
[-N(CH2CH:z)20] ring attached through nitrogen to 
the alkyl, cl-IO alkyl with a piperidine ring attached 50 
through nitrogen to the alkyl, cl-IO alkyl with a pyr-
rolidine ring attached through nitrogen to the alkyl, 
C1_20 alkyl with an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1_IO with an attached 4-py-
ridyl group, cl-IO with an attached 3-pyridyl group, 55 
Cl-IO with an attached 2-pyridyl group, Cl-IO With an 
attached cyclohexyl group, -NH-CH2CH2-(4 -hy-
droxyphenyl), -NH-CH2CH2-(3-indolyl), 
CH2CH(OH)-Ar2 and (CH2)n-Heterocycle2; 
K is selected from the group consisting of halogen, C1_10 60 
alkyl, C1_IO perfluoroalkyl, C1_10 alkoxy, N02, CN, 
OH, C02H, amino, C1_IO alkylamino, C2_12 dialky-
lamino, CcCIO acyl, and cl-IO alkoxy-CO-, and 
C1_IO alkyl-S-; 
Ar2 is selected from the group consisting of phenyl, 65 
phenyl monosubstituted with J, phenyl disubstituted 
with J, phenyl trisubstituted with J, pentafiuorophenyl, 
18 
C6Hi3-0R
2), C6Hi4-0R2), C6H3(3,4-(0R2)i, 
C6H2(2,4,6 -(OR2h, 1-naphthyl monosubstituted with 
J, 1-naphthyl disubstituted with J, 2-naphthyl, 2-naph-
thyl monosubstituted with J, 2-naphthyl disubstituted 
with J, 2-pyridyl, 2-quinolinyl, and 1-isoquinolinyl; 
R2 represents C1_4 alkyl substituted with phenyl, phenyl 
and phenyl substituted with J. 
Heterocycle2 is selected from the group consisting of 
2-furyl, 2-furyl monosubstituted with J, 2-tetrahydro-
furyl, 2-pyridyl, 2-pyridyl monosubstituted with J, 
3-pyridyl, 3-pyridyl monosubstituted with J, 4-pyridyl, 
4-pyridyl monosubstituted with J, 2-pyrazinyl, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 
J, 1-tetrahydroquinolinyl, 2-tetrahydroisoquinolinyl, 
3-indolyl, 2-pyridyl-N-oxide, 3-pyridyl-N-oxide, 4-py-
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comprising the steps: 
(a) Protecting the a-ketone carbonyl of a peptidyl a-ke-
toester with the structures 
M-CO-AA2-AA 1-COOR6 and 
M-CO-AA3-AA2-AA1-COOR6 , 
wherein 
R6 is selected from the group consisting of C1_6 alkyls 
and C1_6 alkyls monosubstituted with phenyl, 
by treatment with a blocking reagent in the presence of a 
Lewis acid in an organic solvent at 0°-100° C. for 1-48 
hours, wherein 
the preferred blocking reagent is 1,2-ethanedithiol; 
the preferred Lewis acids are selected from the group 
consisting of BF3.Eti0, 4-toluene sulfonic acid, A1Cl3 
and ZnC12; 
the preferred organic solvents are selected from the group 
consisting of CH2Cl2, CHC13 , Et20 and THF; 
(b) Treating the product with a primary amine RNH2 in an 
organic solvent at 0°-100° C. for 1-72 hours, wherein 
the preferred organic solvents are selected from the group 
consisting of EtOH, THF, CH2Cl2 and DMF; 
(c) Removing the blocking group from the a-carbonyl to 
give the desired peptidyl a-ketoamide. 
We have also discovered another process for the synthesis 




M is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, C1_4 alkyl disubstituted 
5,514,694 
19 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxr, dis-
ubstituted with phenyl, Ar1CH20-, Ar 0-, 
Ar1CH2NH-, Ar1NH- and Heterocycle1(CH2)q-; 5 
Ar1 is selected from the group consisting of phenyl, 
phenyl monosubstituted with J, phenyl disubstituted 
with J, 1-naphthyl, 1-naphthyl monosubstituted with J, 
2-naphthyl, and 2-naphthyl monosubstituted with J; 
J is selected from the group consisting of halogen, OH, 10 
CN, N02, NH2, COOH, C02Me, C02Et, CF3 , C1_4 
alkoxy, cl-4 alkylamine, c2-8 dialkylamine, cl-4 per-
fluoroalkyl, and -N(CH2CH2)20; 
Heterocycle 1 is selected from the group consisting of 
2-furyl, 2-tetrahydrofuryl, 2-pyridyl, 3-pyridyl, 4-py- 15 
ridyl, 2-pyrazinyl, 2-quinolinyl, 1-tetrahydroquinoli-




AA1, AA2 and AA3 are side chain blocked or unblocked 
a-amino acids with the L configuration, D configura-
tion, or DL configuration at the a-carbon selected 
independently from the group consisting of alanine, 
valine, leucine, isoleucine, histidine, proline, methion- 25 
ine, methionine sulfoxide, phenylalanine, serine, threo-
nine, phenylglycine, norleucine, norvaline, arginine, 
lysine, tryptophan, glycine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, alpha-
aminobutyric acid, 0-methylserine, 0-ethylserine, 30 S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-COOH, alpha-aminohep-
tanoic acid, NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-
CH(CH2-cyclobutyl)-COOH, NH2-CH(CH2-cyclo- 35 
propyl)-COOH, NH2-CH(CH2-l-naphthyl)-
COOH, NH2-CH(CH2-2-naphthyl)-COOH, 5,5,5-
trifluoroleucine, and hexafluoroleucine; 
R is selected from the group consisting of H, C1_20 alkyl, 
cl-20 cyclized alkyl, cl-20 alkyl with a phenyl group 40 
attached to the cl-20 alkyl, cl-20 cyclized alkyl with an 
attached phenyl group, cl-20 alkyl with an attached 
phenyl group substituted with K, C1_20 alkyl with an 
attached phenyl group disubstituted with K, C1_20 alkyl 
with an attached phenyl group trisubstituted with K, 45 
cl-20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)z0] ring attached through nitrogen to 
the alkyl, cl-10 alkyl with a piperidine ring attached 
through nitrogen to the alkyl, cl-10 alkyl with a pyr- 50 
rolidine ring attached through nitrogen to the alkyl, 
C1_20 alkyl with an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1_10 with an attached 4-py-
ridyl group, cl-10 with an attached 3-pyridyl group, 
cl-10 with an attached 2-pyridyl group, cl-10 with an 55 
attached cyclohexyl group, -NH-CH2CH2-(4-hy-
droxyphenyl), -NH-CH2CH2-(3-indolyl), 
CH2CH(OH)-Ar2 and (CH2)n-Heterocycle2; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, N02, CN, 60 
OH, C02H, amino, C1_10 alkylamino, C2_12 dialky-
lamino, Ci-C10 acyl, and C1_10 alkoxy-CO-, and 
C1_10 alkyl-S-; 
Ar2 is selected from the group consisting of phenyl, 
phenyl monosubstituted with J, phenyl disubstituted with J, 65 
phenyl trisubstituted with J, pentafluorophenyl, C6Hi3-
0R2), C6H4(4-0R2), C6H3(3,4-(0R2)z, C6H2 (2,4,6-(0R2)J, 
20 
1-napthyl, 1-napthyl monosubstituted with J, 1-naphthyl 
disubstituted with J, 2-naphthyl, 2-naphthyl monosubsti-
tuted with J, 2-naphthyl disubstituted with J, 2-pyridyl, 
2-quinolinyl, and 1-isoquinolinyl; 
R2 represents C1_4 alkyl substituted with phenyl, phenyl 
and phenyl substituted with J. 
Heterocycle2 is selected from the group consisting of 
2-furyl, 2-furyl monosubstituted with J, 2-tetrahydro-
furyl, 2-pyridyl, 2-pyridyl monosubstituted with J, 
3-pyridyl, 3-pyridyl monosubstituted with J, 4-pyridyl, 
4-pyridyl monosubstituted with J, 2-pyrazinyl, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
1-isoquinolinyl, 1-isoquinolinyl monosubstituted with 
J, 1-tetrahydroquinoliny 1, 2-tetrahydroisoquinoliny 1, 
3-indolyl, 2-pyridyl-N-oxide, 3-pyridyl-N-oxide, 4-py-
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Me ~I '--.N N 
and A I }-
o N N . 
I 
Me 
comprised of the steps: 
(a) Hydrolyzing a peptidyl a-ketoester with the structures 
M-CO-AA2-AA1-COOR6 and 
M-CO-AA3-AA2-AA 1-COOR6 , 
wherein 
R 6 is selected from the group consisting of C1_6 alkyls and 
C1_6 alkyls monosubstituted with phenyl; by treating 
the peptidyl a-ketoester with a hydrolysis reagent in an 
appropriate solvent at 0°- 100° c. for 1-24 hours to 
give the corresponding peptidyl a-ketoacid, wherein 
the preferred hydrolysis reagents are selected from the 
group consisting of NaOH, KOH, EtONa and EtOK; 
the preferred solvent are selected from the group consist-
ing of water, MeOH, EtOH, THF and DMF; 
(b) Coupling the product peptidyl a-ketoacid with a 
primary amine RNH2 in an organic solvent at 0°-100° 
C. for 1-72 hours to give the desired peptidyl a-ke-
toamide, 
wherein 
the preferred coupling conditions are selected from the 
group consisting of treatment with 1, 1-carbonyldimi-
dazole, treatment with dicyclohexylcarbodiimide, and 
treatment with dicyclohexylcarbodiimide-1-hydroxy-
benzotriazole; 
the preferred organic solvents are selected from the group 
consisting of CH2Cl2, CHC13 , DMF and THE 
We have also discovered a process for the synthesis of 






M is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, cl-4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkox~ dis- 5 
ubstituted with phenyl, Ar1CH20-, Ar 0-, 
Ar1CH2NH-, Ar1NH- and Heterocycle1 (CH2)q-; 
Ar1 is selected from the group consisting of phenyl, 
phenyl monosubstituted with J, phenyl disubstituted 
with J, 1-naphthyl, 1-naphthyl monosubstituted with J, 10 
2-naphthyl, and 2-naphthyl monosubstituted with J; 
22 
with J, phenyl trisubstituted with J, pentafiuorophenyl, 
C6Hi3-0R2), C6Hi4-0R2), C6H3(3,4-(0R2)z, C6H2 
(2,4,6-(0R2h, 1-naphthyl, 1-naphthyl monosubstituted 
with J, 1-naphthyl disubstituted with J, 2-naphthyl, 
2-naphthyl monosubstituted with J, 2-naphthyl disub-
stituted with J, 2-pyridyl, 2-quinolinyl, and 1-isoquino-
linyl; 
R2 represents C1_4 alkyl substituted with phenyl, phenyl 
and phenyl substituted with J. 
Heterocycle2 is selected from the group consisting of 
2-furyl, 2-furyl monosubstituted with J, 2-tetrahydrofuryl, 
2-pyridyl, 2-pyridyl monosubstituted with J, 3-pyridyl, 
3-pyridyl monosubstituted with J, 4-pyridyl, 4-pyridyl 
monosubstituted with J, 2-pyrazinyl, 2-quinolinyl, 2-quino-
J is selected from the group consisting of halogen, OH, 
CN, N02, NH2, COOH, C02Me, C02Et, CF3 , C1_4 
alkoxy, C1_4 alkylamine, C2-8 dialkylamine, C1_4 per-
fiuoroalkyl, and -N(CH2CH2)zO; 
Heterocycle1 is selected from the group consisting of 
2-furyl, 2-tetrahydrofuryl, 2-pyridyl, 3-pyridyl, 4-py-
ridyl, 2-pyrazinyl, 2-quinolinyl, 2-tetrahydroquinoli-
nyl, 1-isoquinolinyl, 1-tetrahydroisoquinolinyl, and 
-N(CH2CH2)zO; 
15 linyl monosubstituted with J, 1-isoquinolinyl, 1-isoquinoli-
nyl monosubstituted with J, 1-tetrahydroquinolinyl, 2-tet-
rahydroisoquinolinyl, 3-indolyl, 2-pyridyl-N-oxide, 
3-pyridyl-N-oxide, 4-pyridyl-N-oxide, 2-(N-methyl-2-pyr-
rolyl), 1-imidazolyl, 1-pyrrolidinyl-2-one, 2-(5-methyl-3-
20 thiazolyl), (CH2)z-NH-biotin; 
q=0-2; 
AA 1, AA 2 and AA 3 are side chain blocked or unblocked 
a-amino acids with the L configuration, D configura-
tion, or DL configuration at the a-carbon selected 
independently from the group consisting of alanine, 25 
valine, leucine, isoleucine, histidine, praline, methion-
ine, methionine sulfoxide, phenylalanine, serine, threo-
nine, phenylglycine, norleucine, norvaline, arginine, 
lysine, tryptophan, glycine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, alpha- 30 
aminobutyric acid, 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-COOH, alpha-aminohep-
tanoic acid, NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2- 35 
CH(CH2-cyclobutyl)-COOH, NH2-CH(CH2-cyclo-
propyl)-COOH, NH2-CH(CH2 - l-naphthyl)-
COOH, NH2-CH(CH2-2-naphthyl)-COOH, 5,5,5-
trifiuoroleucine, and hexafiuoroleucine; 
R is selected from the group consisting of H, C1_20 alkyl, 
40 
0 Me 
Me ~I '-..N N 
and A I }-
o N N . 
I 
Me 
consisting of treating a peptidyl a-enolester derived 




R6 is selected from the group consisting of C1_6 alkyls and 
C1_6 alkyls monosubstituted with phenyl; 
with a primary amine RNH2 in an organic solvent at 
0°-100° C. for 1-72 hours to give the desired peptidyl 
a-ketoamide, wherein 
the preferred organic solvents are selected from the group 
consisting of CH2Cl2 , EtOH, DMF and THE 
Representative Compounds 
The following compounds are representatives of the 
invention: 
Z-Leu-Abu-CONH-(CH2)z0H 




c!-20 cyclized alkyl, c!-20 alkyl with a phenyl group 
attached to the c!-20 alkyl, c!-20 cyclized alkyl with an 
attached phenyl group, c!-20 alkyl with an attached 
phenyl group substituted with K, C1_20 alkyl with an 45 
attached phenyl group disubstituted with K, C1_20 alkyl 
with an attached phenyl group trisubstituted with K, 
cl-20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 50 
alkyl, cl-10 alkyl with a piperidine ring attached 
through nitrogen to the alkyl, cl-10 alkyl with a pyr-
rolidine ring attached through nitrogen to the alkyl, 
C1_20 alkyl with an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1_10 with an attached 4-py- 55 
ridyl group, c!-10 with an attached" 3-pyridyl group, 
cl-10 with an attached 2-pyridyl group, cl-10 with an 
attached cyclohexyl group, -NH-CH2CH2-(4hy-
droxyphenyl), -NH-CH2CH2-(3-indolyl), 
CH2CH(OH)-Ar2 and (CH2)n-Heterocycle2 ; 60 Z-Leu-Abu-CONH-CH2-C6H8[1,3,3-(CH3) 3-5-0H] 
Z-Leu-Abu-CONH-(CH2)zC6H4 ( 4-0H) 
Z-Leu-Abu-CONH-(CH2)zC6H4 (2-0CH3) 
Z-Leu-Abu-CONH-(CH2)zC6H4 (3-0CH3) 
Z-Leu-Abu-CONH-(CH2 )zC6Hi4-0CH3 ) 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, 
OH, C02H, amino, C1_10 alkylamino, C2_12 dialky-
lamino, Ci-C10 acyl, and C1_10 alkoxy-CO-, and 
C1-l0 alkyl-S-; 
Ar2 is selected from the group consisting of phenyl, 
phenyl monosubstituted with J, phenyl disubstituted 
65 Z-Leu-Abu-CONH-CH2C6H3[3,5-(0CH3)z] 
Z-Leu-Abu-CONH-CH2CH(OH)Ph 




Z-Leu-Abu-CONH-CH2CH(OH)C6H4 [ 4-N(CH3)z] 
Z-Leu-Abu-CONH-CH2CH(OH)C6F5 





Z-Leu-Abu-CONH-CH2CH(OH)C6H4 -3-0C6H3(3,4-Cl2 ) 








Z-Leu-Phe-CONH-CH2 CH(OH)C6 H4 ( 4-0Ph) 
Z-Leu-Phe-CONH-CH2CH(OH)C6H4 ( 4-0CH2Ph) 
Z-Leu-Phe-CONH-CH2CH(OH)C6H4 -3-0C6H4 (3-CF3) 




























Z-Leu-Phe-CONH-CHr 1-isoquinolinyl 15 
Z-Leu-Phe-CONH-(CH2h- l-tetrahydroquinolinyl 
Z-Leu-Phe-CONH-(CH2h-2-tetrahydroisoquinolinyl 






















Materials and Experimental Methods 
HEPES, heparin, and A23187 were obtained from Cal-
10 biochem. Suc-Leu-Tyr-AMC and chromogenic substrates 
were obtained from Sigma. Calpain I was purified from 
human erythrocytes according to the method of Kitahara 
(Kitahara et al., J. Biochem. 95, 1759-1766) omitting the 
Blue-Sepharose step. Calpain II from rabbit muscle and 
15 cathepsin B were purchased from Sigma. Papain was pur-
chased from Calbiochem. 
Assay of inhibitory Potency. 
Peptide a.-ketoarnides were assayed as reversible enzyme 
inhibitors. Various concentrations of inhibitors in Me2 SO 
20 were added to the assay mixture which contained buffer and 
substrate. The reaction was started by the addition of the 
enzyme and the hydrolysis rates were followed spectropho-
tometrically or fluorimetrically. 
Calpain I from human erythrocytes and calpain II from 
25 rabbit were assayed using Suc-Leu-Tyr-AMC [Sasaki et al., 
J. Biol. Chem. 259, 12489-12494 (1984); incorporated 
herein by reference], and the AMC (7-amino-4-methylcou-
marin) release was followed fluorimetrically (excitation at 
380 nm, and emmision at 460 nm). Calpains were assayed 
30 in 25 mM Tris pH=8.0, 10 mM CaC12. Fluorescence was 
followed using a Gilson FL-lA fluorometer or a Perkin-
Elmer 203 Fluorescence spectrometer. Cathepsin B was 
assayed in 20 mM sodium acetate pH=5.2, 0.5 mM dithio-
threitol using Bz-Phe-Val-Arg-p-nitroanilide as substrate. 
35 Alternately, cathepsin B was assayed with Z-Arg-Arg-AFC 
[Barrett and Kirschke, Methods Enzymol. 80, 535-561 
(1981); incorporated herein by reference], and the AFC 
(7-amino-4-trifluoromethylcoumarin) release was followed 
fluorimetrically (excitation at 400 nm and emrnision at 505 
40 nm). Papain was assayed in 100 mM KP04 , 1 mM EDTA, 
2.5 mM cysteine pH=6.0 using Bz-Arg-AMC or Bz-Arg-NA 
[Kanaoka et al., Chem. Pharm. Bull. 25, 3126-3128 (1977); 
incorporated herein by reference] as a substrate. The AMC 
(7-amino-4-methylcoumarin) release was followed fluori-
45 metrically (excitation at 380 nm, and emmision at 460 nm). 
Enzymatic hydrolysis rates were measured at various sub-
strate and inhibitor concentrations, and Kr values were 
determined by either Lineweaver-Burk plots or Dixon plots. 
A O.lM Hepes, 0.5M NaCl, pH 7.5 buffer was utilized for 
50 human leukocyte elastase (HLE), porcine pancreatic elastase 
(PPE), chymotrypsin and cathepsin G. A 0.1 Hepes, 0.01 M 
CaC12 , pH 7.5 buffer was utilized for trypsin, plasmin, and 
coagulation enzymes. A 50 mM Tris.RC!, 2 mM EDTA, 5 
mM cysteine, pH 7.5 was used as a buffer for papain. A 88 
55 mM KH2P04 , 12 mM NazHP04 , 1.33 mM EDTA, 2.7 mM 
cysteine, pH 6.0 solution was used as a buffer for cathepsin 
B. A 20 mM Hepes, 10 mM CaC12 , 10 mM mercatoethanol, 
pH 7.2 buffer was utilized for calpain I and calpain II. 
HLE and PPE were assayed with MeO-Suc-A!a-Ala-Pro-
60 Val-NA and Sue-Ala-Ala-Ala-NA, respectively [Nakajima 
et al., J. Biol. Chem. 254, 4027--4032 (1979); incorporated 
herein by reference]. Human leukocyte cathepsin G and 
chymotrypsin Aa were assayed with Suc-Val-Pro-Phe-NA 
[Tanaka et al., Biochemistry 24, 2040-2047 (1985); incor-
65 porated herein by reference]. The hydrolysis of peptide 
4-nitroanilides was measured at 410 nm [e410=8800 M-1cm-
1; Erlanger et al., Arch. Biochem. Biophys. 95, pp 271-278 
5,514,694 
25 
(1961); incorporated herein by reference]. Trypsin, throm-
bin, human plasma kallikrein, porcine pancreatic kallikrein, 
human factor Xla, and human plasmin were assayed with 
Z-Arg-SBzl or Z-Gly-Arg-SBu-i [McRae et al., Biochemis-
try 20, 7196-7206 (1981); incorporated herein by refer- 5 
ence]. All peptide thioester hydrolysis rates were measured 
with assay mixtures containing 4,4'-dithiodipyridine [e324= 
19800 M-1cm-1; Grasetti & Murray, Arch. Biochem. Bio-
phys. 119, 41-49 (1967); incorporated herein by reference]. 
10 
Structure-Activity Relationships 
Table 1 shows the inhibition constants (K1) for calpain I, 
calpain II and cathepsin B. Changing the R group on the 
amide significantly improves the inhibitory potency toward 15 
calpains. Dipeptide a-ketoamides with Abu, Phe, and Nva in 
the P 1 site and Leu in the P 2 site are potent inhibitors of these 
cysteine proteases. The presence of a hydrogen bond donor 
in the S1 ' subsite of the cysteine proteases which may be 
interacting with the N-H on the ketoamide functional group 20 
is indicated since disubstituted amides were much less 
effective inhibitors. Derivatives of Z-Leu-AA-CONHR 
where the R group contained a hydroxy or alkoxy group, 
such as (CH2)50H and CH2CH(OC2H5}i, are very good 
inhibitors of the calpains. The prescence of an aromatic 
group in P 1' position of the peptide ketoamide inhibitor 
resulted in improved inhibitory potency for calpains which 
indicates the prescence of hydrophobic residues in the S' 
subsites of both calpains. The derivatives Z-Leu-AA-
CONH(CH2)nR where R was phenyl, phenyl substituted 
with hydroxy or alkoxy groups and naphthyl, are also very 
good inhibitors of calpains and cathepsin B. Derivatives of 
Z-Leu-Abu-CONH(CH2)nR where the R group contained a 
heterocylic group which has both a hydrophobic moiety with 
25 
30 
an electronnegative atom, are among the best inhibitors for 35 
calpains and cathepsin B. For example Z-Leu-NvaCON-
HCH2-2-pyridyl is the best inhibitor of calpain I. Z-Leu-
Abu-CONHCH2-2-pyridyl is the best inhibitor of calpain II 
respectively in this series, but its isomers, Z-Leu-Abu-
CONH-CH2-3-pyridyl and Z-Leu-Abu-CONH-CH2-4- 40 
pyridyl, are substantially poorer inhibitors. 
TABLE 1 
Inhibition of Cysteine Proteases by Peptide a-Ketoamides 
with the Structures Z-Leu-AA-CONHR. 
R 






























































Inhibition of Cysteine Proteases by Peptide a-Ketoamides 












































































Table 2 shows the inhibition constants (K1) of Z-Leu-
AA-CONH-CH2CH(OH)R. The hydrophobic moiety 
substituted with CH2CH-X (X=electronegative atoms such 
as 0, N) resulted in good inhibitor structures. Z-Leu-Abu-
CONH-CH2CH(OH)C6F5 is the best inhibitor for calpain 
I, and Z-Leu-Abu-CONH-CH2CH(OH)Ph is the best 
inhibitor for calpain II respectively in this series. 
TABLE 2 
Inhibition of Cysteine Proteases by Peptide a-Ketoamides 
with the Structures Z-Leu-AA-CONH-CH2CH(OH)-R. 
R 















































Inhibition of Cysteine Proteases by Peptide a-Ketoamides 
with the Structures Z-Leu-AA-CONH-CH2CH(OH)-R. 
K,(µM) 
R Cal I Cal II CatB 
C6H4 (4-0Ph) 0.20 




AA = Norvaline 
Ph 7.8 11 
In general, replacement of the Z group (PhCH20CO-) 
28 
TABLE 4-continued 









15 C6H4 (3-0Pb) C6H.(4-0Ph) 
CH2CH(OH)-C6H4 ( 4-0CH2Ph) 













(K1 = 15) 
30 
64 
by related aromatic groups also resulted in good inhibitor 
20 








Inhibition of Cysteine Proteases by Peptide a-ketoamides 
with the Structures M 1CO-Leu-AA-CONH-R. 
R 





























































Table 4 shows the inhibition constants (IC50), for human 
leuckocyte elastase (HLE) and cathepsin G (Cat G). Dipep-
tidyl a-ketoamides with Abu and Phe in the P 1 site are potent 
inhibitors of HLE. 
R 
TABLE 4 
Inhibition of Serine Proteases by Peptide a-ketoamides the 
Structures Z-Leu-AA-CONH-R. 
ICso(µM) 
HLE Cat G 
AA = a-aminobutyric acid 
H >120 NI 
n-Pr >120 >217 
n-Bu 63 148 
i-Bu 78 134 
C1H1s 52 >116 
C8H17 45 >217 
CJI19 78 150 
CH2-8-caffeine 156 
(CH2),NH-biotinyl 38 
AA = phenylalanine 
25 H 100 80 
Et 74 91 
n-Pr 44 65 
n-Bu 16 68 
(K1 = 11) (K1 =4.9) 
i-Bu 20 45 
30 (K1 = 10) (K1 =21) 
sec-Bu 50 128 
















40 C6H3(3,4-(0CH2Ph),) 22 66 
45 
50 
(CH2)3-4-morpholinyl >222 136 
Inhibition Mechanism. 
A crystal structure of one a-ketoester bound into the 
active site of porcine pancreatic elastase has been completed 
and a schematic drawing of the interactions observed is 
shown below. The active site Set-195 oxygen of the enzyme 
has added to the carbonyl group of the ketoester to form a 
tetrahedral intermediate which is stabilized by interactions 
with the oxyanion hole. This structure resembles the tetra-
hedral intermediate involved in peptide bond hydrolysis and 
proves that a-ketoester are transition-state analogs. His-57 is 
55 hydrogen bonded to the carbonyl group of the ester func-
tional group, the peptide backbone on a section of PPB' s 
backbone hydrogen bonds to the inhibitor to form a ~-sheet, 
and the benzyl amide is directed toward the S' subsites. The 
side chain of the P 1 amino acid residue is located in the S 1 
pocket of the enzyme. Interactions with ketoamides would 
be similar except for that there would be the possibility of 
forming an additional hydrogen bond with the NH group of 
the ketoamide functional group. If R is longer substutuent, 
then they would make favorable interactions with the S' 






H b oxyanion 





The active site of cysteine proteases share several features 
in common with serine proteases including an active site 
histidine residue. In place of the Ser-195, cysteine proteases 
have an active site cysteine residue which would add to the 
ketonic carbony 1 group of the peptide ketoamides to form an 20 
adduct very similar to the structure depicted above except 
with a cysteine residue replacing the serine-195 residue. 
Additional interactions would occur between the extended 
substrate binding site of the cysteine protease and the 
inhibitor which would increase the binding affinity and 25 
specificity of the inhibitors. 
Inhibitor Design and Selection. 
The peptide a-ketoamide derivatives, as shown in the 
above crystal structure, bind to the enzymes using many of 
the interactions that are found in complexes of a particular 30 
individual enzyme with its substrates. In order to design an 
inhibitor for a particular serine or cysteine protease, it is 
necessary to: 1) find the amino acid sequences of good 
peptide substrates for that enzyme, and 2) place those or 
similar amino acid sequences into a a-ketoamide structure. 35 
Additional interactions with the enzyme can be obtained by 
tailoring the R group of the inhibitor to imitate the amino 
acid residues which are preferred by an individual protease 
at the S1 ' and S2 ' subsites. For example, ketoamides with 
R=alkyl substituted with phenyl would interact effectively 40 
with serine and cysteine proteases which prefer Phe, Tyr, Trp 
residues at P1' and/or P2 '. Likewise, the M1 group can be 
tailored to interact with the S subsites of the enzyme. This 
design strategy will also work when other classes of peptide 
inhibitors are used in place of the peptide substrate to gain 45 
information on the appropriate sequence to place in the 
ketoamide inhibitor. Thus, we are able to predict the struc-
ture of new inhibitors for other serine and cysteine proteases 
based on knowledge of their substrate specificities. Once a 
good inhibitor structure for a particular enzyme is found, it 50 
is then possible to change other characteristics such as 
solubility or hydrophobicity by adding substituents to the 
M1 or R groups. 
Suc-Phe-Leu-Phe-NA is an excellent substrate for chy-
motrypsin, cathepsin G, and most cell chymases. Thus, the 55 
corresponding a-ketoamide will be an excellent inhibitor for 
these chymotrypsin-like enzymes. In the case of the cysteine 
protease calpain, a good inhibitor sequence is Ac-Leu-Leu-
Nle-H. We have found that Ketoamides, related in structure 
such as Z-Leu-Abu-CO-NHR and Z-Leu-Phe-CO-NHR 60 
are potent inhibitors for calpain. 
In Vitro Uses. 
30 
S' suhsites 
or in suspension. The cysteine protease inhibitors of this 
invention would be useful in a variety of experimental 
procedures where proteolysis is a significant problem. Inclu-
sion of these inhibitors in a radioimmunoassay experiments 
would result in higher sensitivity. The use of these inhibitors 
in plasma fractionation procedures would result in higher 
yields of valuable plasma proteins and would make purifi-
cation of the proteins easier. The inhibitors disclosed here 
could be used in cloning experiments utilizing bacterial 
cultures, yeast and human cells to yield a purified cloned 
product in higher yield. 
The novel compounds of this invention are effective in the 
prevention of unnecessary proteolysis caused by chymot-
rypsin-like and elastase-like enzymes in the process of 
purification, transport and storage of peptides and proteins 
as shown in Tables I, II, ill, and IV by effective inhibition 
of chymotrypsin, elastase, and cysteine proteases. 
In Vivo Uses. 
Peptide a-ketoamide can be used to control protein turn-
over, muscular dystrophy, myocardial tissue damage, tumor 
metastasis, and bone resorption as shown in Table I, II, and 
ill by effective inhibition of lysosomal cathepsin B. Peptide 
a-ketoamides can also be used as neuroprotectants or for the 
treatment of ischemia, stroke, restenosis or Alzheimer's 
disease as shown in Table I, II, and ill by effective inhibiton 
of calpain I and calpain II. 
Considerable evidence has shown that leukocyte elastase 
and/or related enzymes play a role in tumor cell metastasis 
[Salo et al., Int. J. Cancer 30, pp 669-673 (1973); Kao et al., 
Biochem. Biophys. Res. Comm. 105, pp 383-389 (1982); 
Powers, J. C. in Modification of Proteins, R. E. Feeney and 
J. R. Whitaker, eds., Adv. Chem. Set 198,Amer. Chem. Soc., 
Wash., D.C. pp 347-367 (1982); all incorporated herein by 
reference], therefore it is suggested that compounds of this 
invention may have anti-tumor activity. 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity due to the destruction of 
lung elastin and alveoli. The destructive changes of lung 
parentchyma associated with pulmonary emphysema are 
caused by uncontrolled proteolysis in lung tissues [Janoff, 
Chest 83, 54-58 (1983); incorporated herein by reference]. 
A number of proteases have been shown to induce emphy-
sema in animals [Marco et al., Am. Rev. Respir. Dis. 104, 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, 349-356 
(1973); incorporated herein by reference], particularly 
human leukocyte elastase [Janoff, ibid 115, 461-478 (1977); 
incorporated herein by reference]. Leukocyte elastase and 
other mediators of inflammation also appear to play a role in 
diseases such as mucocutaneous lymph node syndrome 
To use the above inhibitors in vitro, they are dissolved in 
an organic solvent such as dimethylsulfoxide or ethanol, and 
are added to an aqueous solution containing cysteine pro-
teases. The final concentration of the organic solvent should 
be less than 25%. The inhibitors may also be added as solids 
65 [Reiger et al., Eur. J. Pediatr. 140, 92-97 (1983); incorpo-
rated herein by reference] and adult respiratory distress 
syndrome [Stockley, Clinical Science 64, 119-126 (1983); 
5,514,694 
31 
~e et al., N. Eng. J. Med. 304, 192-196 (1981);Rinaldo, 
1b1d 301,900-909 (1982); incorporated herein by reference]. 
32 
tide acid as shown in the following scheme (Charles et al., 
J. Chem. Soc. Perkin 1, 1139-1146, 1980). 
M 1-AA-AA-0H--)Enol Ester--)M1-AA-AA--CO-O-R 
The precursor peptide can be prepared using standard 
peptide chemistry which is well described in publications 
such as The Peptides, Analysis, Synthesis, Biology, Vol. 1-9, 
published in 1979-1987 by Academic Press and Houben-
Weyl Methoden der Organischen Chemie, Vol. 15, Parts 1 
and 2, Synthese van Peptiden, published by Georg Thieme 
Verlag, Stuttgart in 1974 (both references incorporated 
herein by reference). 
The M1CO-- group can be introduced using a number of 
different reaction schemes. For example it could be intro-
duced directly on an amino acid as shown in the following 
scheme (top), or the M1CO-- group could be introduced by 
reaction with an amino acid ester, followed by removal of 
the ester group to give the same product (middle), or the 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of emphy-
sema and inflammation [Ottemess et al., editors, Advances 5 
in Inflammation Research, Vol. 11, Raven Press 1986; 
incorporated herein by reference]. Prophylactic administra-
tion of an inhibitor of elastase significantly diminishes the 
extent of elastase-induced emphysema [Kleinerman et al., 
Am. Rev. Resir. Dis. 12 1,381-387 (1980); Lucey et al., Eur. 10 
Respir. J. 2,421-427 (1989); incorporated herein by refer-
ence]. Thus the novel inhibitors described here should be 
useful for the treatment of emphysema and inflammation. 
~l~tas~ i~bitors have .been used orally, by injection, or by 
mstlllation m the lungs m animal studies (Powers, Am. Rev. 15 
Respir. Dis., 127, s54-s58 (1983); Powers and. Bengali, Am. 
Rev. Respir. Dis. 134, 1097-1100 (1986); these two articles 
are incorporated herein by reference). The inhibitors 
described above can be used by any of these routes. 
20 M1 CO- gro~p could be introduced by deblocking z group from ketoamide then reaction with an acid or chloride 
(bottom). 
Drug Delivery. 
F~r. therapeutic use, the peptide a-ketoamides may be 
admm1stered orally, topically or parenterally. The term 
parenteral as used includes subcutaneous injection, intrave-
nous, intramuscular, intrastemal injection or infusion tech-
niques. The dosage depends primarily on the specific for- 25 
mulation and on the object of the therapy or prophylaxis. 
The amount of the individual doses as well as the adminis-
tration is best determined by individually assessing the 
particular case. 
The pharmaceutical compositions containing the active 30 
ingredient may be in a form suitable for oral use, for 
example as tablets, troches, lozenges, aqueous or oily sus-





The techniques for introduction of the M1 CO group is 
well documented in the The Peptides, Houben-Weyel, and 
many other textbooks on organic synthesis. The M1CO--
AA-AA-OH derivatives could then be used directly in 
the Dakin-West reaction. The R group in the ketoester 
struc~res ~s introduced during the Dakin-West reaction by 
react10n with an oxalyl chloride Cl--CO--CO--O--R. 
or soft capsules or syrups or elixirs. Dosage levels of the 
order to 0.2 mg to 140 mg per kilogram of body weight per 35 
day are useful in the treatment of above-indicated conditions 
(10 mg to 7 gms per patient per day). The amount of active 
ingredient that may be combined with carrier materials to 
produce a single dosage form will vary depending upon the 
host treated and the particular mode of administration. 
. ~etoamides M1 CO--AA-AA--CONHR were prepared 
mdrrectly from the ketoesters. The ketone carbonyl group is 
first protected as shown in the following scheme and then the 
ketoarnide is prepared by reaction with an amine RNH . The 
40 2 product is easily isolated from the reaction mixture when 
For injection, the therapeutic amount of the peptide a-ke-
toamides or their pharmaceutically acceptable salts will 
normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
muscular or subscutaneous injection. Accordingly, pharma- 45 
ceutical compositions for parenteral administration will con-
tain in a single dosage form about 10 mg to 7 gms of the 
compounds per dose. In addition to the active ingredient, 
these pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in the 50 
range from 3.5 to 7 and also sodium chloride, mannitol or 
sorbitol for adjusting the isotonic pressure. 
A composition for topical application can be formulated 
as an aqueous solution, lotion, jelly or an oily solution or 
suspention. A composition in the form of an aqueous solu- 55 
tion is obtained by dissolving the compounds of this inven-
tion in aqueous buffer solution of pH 4 to 6.5 and if desired, 
adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds of this 
invention in an oil, optionally with the addition of a swelling 60 
agent such as aluminium stearate and/or a surfactant. 
SYNTHETIC METHODS 
The a-ketoarnide inhibitors are prepared from the corre- 65 
sponding a-ketoesters. The a-ketoester are prepared by a 
two step Dakin-West reaction from the corresponding pep-
using this procedure. This procedure will also work with 
?ther ketoi;ie protecting groups. In addition, the correspond-
mg ketoac1d can be used as a precursor to the a-ketoamide 
via c~upling with an amine RNH2 using standard peptide 





Mi CO-Leu T If 
R1 0 
The techniques for synthesis of a wide variety of amines 
are described in many publications. For example, Evans et 
5,514,694 
33 
al. [J. Org. Chem. 39, 914 (1974); incorporated herein by 
reference] reported the syntheses of phenylethanol deriva-
tives with alkylamino, alkoxyamino and phenyloxyamino 
groups. Katrizk.y et al. [J. Chem. Soc. 2404-2408 (1956); 
incorporated herein by reference], Fife et al. [Heterocycles, 5 
22(1), 93-96 (1984), Heterocycles, 22(5), 1121-1124 
(1984); incorporated herein by reference], and Isoda et al. 
[Chemical and Pharmaceutical Bulletin, 28, 1408-14 
14(1980); incorporated herein by reference] reported the 
syntheses of pyridine derivatives with alkylamino and 10 
COOR groups. Nagata et al. [Yakugaku 'Zasshi, 83,679-682 
(1963); incorporated herein by reference] reported the syn-
theses of quinoline derivatives with alkylamino groups. 
Zimmer et al. [Tetrahedron Letters, 24, 2805-2807 (1968); 
incorporated herein by reference]reported the syntheses of 15 
isoquinoline derivatives with alkylamino groups. Aroyan et 
al. [lzv. Akad. Nauk Arm. SSR, KMm. Nauki, 18(1), 76-82 
(1965); incorporated herein by reference] reported the syn-
theses of tetrahydroquinoline derivatives with alkylamino 
groups. Yonan, [U.S. Pat. No. 3,245,997(Cl. 260-288), Apr. 20 
12, 1966.2 pp; incorporated herein by reference] reported 
the syntheses of tetrahydroisoquinoline derivatives with 
alkylamino groups. Rybar et al. [Chem. Commun. 35, 
1415-1433 (1970); incorporated herein by reference], 
Golovchinskaya et al. [J. General Chem. 22, 599-603 25 
(1952); incorporated herein by reference], and Nantka-
Namirski et sl. [Acta. Polan. Pharm. 1, 5-12 (1974); incor-
porated herein by reference] reported the syntheses of caf-
feine derivatives with alkylamino groups. Goldberg et al. [J. 
Chem. Soc. 1372 (1947); incorporated herein by reference] 30 
reported the syntheses of methylthiazole derivatives with 
alkylamino groups. Mizuno et al. [J. Org. Chem. 39, 1250 
(1974); incorporated herein by reference] reported the syn-
theses o.f pyridine-N-oxide derivatives with alkylamino 
groups. Wade [J. Heterocyclic Chem. 23, 981 (1986)] 35 




chromatography using CHC13/CH30H 10:1 (40% yield). 
White solid, single spot on TLC, R.r=0.42 (CHC13'CH3JI 
10:1), mp 151°- 154° C. 1H NMR (CDC13) ok, MS (FAB) 
m/e=422 (M+l). Anal: calcd. for C 21H31 N3 0 6 , 421; C, 
59.84; H, 7.41; N, 9.97. Found: C, 59.11; H, 7.44; N, 9.81. 
Example 3 
Z-Leu-Abu-CONH-(CH2)zO(CH2)zOH. 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 2-(2-aminoethoxy) 
ethanol by the procedure described in Example 1, and 
purified by column chromatography using CHC13'CH30H 
10:1 (34% yield). White solid, single spot on TLC, R.r=0.42 
(CHC13'CH30H 10:1),mp 103°-105° C. 1H NMR (CDC13 ) 
ok, MS (FAB) m/e=466 (M+l). Anal: calcd. for 
C23H35N30 7 , 465; C, 59.30; H, 7.58; N, 9.02. Found: C, 
59.23; H, 7.58; N, 9.01. 
Example 4 
Z-Leu-Abu-CONH-CH2CH(OCH3)z. 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and aminoacetaldehyde 
dimethylacetal by the procedure described in Example 1, 
and purified by column chromatography using CHC13/ 
CH30H 20:1 (25% yield). White solid., single spot on TLC, 
R.r=0.47 (CHC13'CH30H 20: 1), mp 99°-102° C. 1H NMR 
(CDC13) ok, MS (FAB) m/e=466 (M+l). Anal: calcd. for 
C23H35N30 7 , 465; C, 59.30; H, 7.58; N, 9.02. Found: C, 
58.95; H, 7.71; N, 9.00. 
Example 5 
Z-Leu-Abu-CONH-CH2CH(OC2H5)z. 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and aminoacetaldehyde 
diethylacetal, and purified by column chromatography using 
CHC13'CH30H 20: 1 (36% yield). White solid, single spot 
The follow detailed examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
Example 1 
40 on TLC, R_r=0.37 (CHC13/CH30H 20: 1), mp 100°-103° C. 
1HNMR (CDC13 ) ok,MS (FAB) m/e=494 (12%, M+l), 448 
(100%, M+l-45). Anal: calcd. for C25H39N30 7 , 493; C, 
60.83; H, 7.96; N, 8.51. Found: C, 60.73; H, 7.98; N, 8.42. 
Z-Leu-Abu-CONH-(CHz)50H. 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 5-amino-1-pentanol. 
To a solution of protected a-ketoester (1 mmol) in ethanol 
45 
(3 mL) was added 5-amino-1-pentanol (3 mmol) and stirred 
overnight at r.t. To the mixture was added AcOEt (25 mL) 50 
and white precipitate was filtered. The filtrate was washed 
with cold lN HCl (2x10 mL), water (lxlO mL), saturated 
NaCl (2x10 mL) and dried over MgS04 • After evaporation 
of the solvent, chromatography on a silica gel column using 
CHC13/CH30H 10: 1 followed by precipitation from AcOEt/ 55 
hexane afforded a white solid (42% yield). Single spot on 
TLC, R.r=0.54 (CHC13'CH30H 10:1), mp 122°-123° C. 1H 
NMR (CDC13 ) ok, MS (FAB) m/e=464 (M+l). Anal: calcd. 
for C24H37N30 6 , 463; C, 62.18; H, 8.04; N, 9.06. Found: C, 





This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 3-aminomethyl-3,5,5, 
-trimethyl-cyclohexanol, and purified by column chroma-
tography using CHC13/CH30H 30:1 (51 % yield). White 
solid, single spot on TLC, R.r=0.55 (CHC13/CH30H30,1), mp 
59°-61° C. 1H NMR(CDC13) ok, MS (FAB) m/e=532 
(M+l).Anal; calcd. forC29H45N30 6,531; C, 65.51; H, 8.53; 
N, 7.90. Found, C, 65.21; H, 8.55, N, 7.81. 
Example 7 
Z-Leu-Abu-CONH-(CH2)zC6H4(4-0H). 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 4-(2-aminoethyl)phe-
nol, and purified by column chromatography using CHC13' 
CH30H 30:1 (60% yield). White solid, single spot on TLC, 
Rf=0.56 (CHC13/CH30H 30:1), mp 151°-153° C. 1H NMR 
This compound was synthesized from 1,3-dithiolane deriva-
tive of Z-Leu-Abu-COOEt and ethanolamine by the proce-
dure described in Example 1, and purified by column 
65 (CDC13) ok, MS (FAB) m/e=498 (M+l). Anal: calcd. for 
C27H35N30 6 , 497; C, 65.17; H, 7.09; N, 8.45. Found, C, 





This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 2-methoxyphenethy- 5 lamine, and purified by column chromatography using 
CHC13'CH30H 50:1), (71 % yield). Yellow solid, single spot 
on TLC, Rr-0.47 (CHC13/CH30H 50:1 ), mp 101°-103° C. 
1H NMR(CDC13) ok, MS (FAB) m/e=512(M+l). Anal; 
calcd. for C28H37N30 6 , 511; C, 65.73; H, 7.29; N, 8.21. 10 
Found, C, 65.50; H, 7.31; N, 8.19. 
Example 9 
Z-Leu-Abu-CONH-(CH2)zC6H4(3-0CH3). 
This compound was synthesized from 1,3-dithiolane 15 
derivative of Z-Leu-Abu-COOEt and 3-methoxyphenethy-
lamine, and purified by column chromatography using 
CHC13/CH30H 50:1 (56% yield). Yellow solid, single spot 
on TLC, Rr-0.46 (CHC13/CH30H 50:1 ), mp 99°-100° C. 
1H NMR (CDC13) ok, MS (FAB) m/e=512 (M+l). Anal: 20 
calcd. for C28H37N30 6 , 511; C, 65.73; H, 7.29; N, 8.21. 
Found, C, 65.62; H, 7.34; N, 8.16. 
36 
(M+ 1). Anal: calcd. for C28H37N30 7 , 527; C, 63.74; H, 7.07; 
N, 7.96. Found, C, 63.44; H, 7.08; N, 7.82. 
Example 14 
Z-Leu-Abu-CONH-CH2CH(OH)C6H2(2,4,6-(0CH3h). 
This compound was synthesized using 2-amino-1(2,4,6-
trimethoxy)phenylethanol and purified by column chroma-
tography using CHC13/CH30H 20:1 followed by CHC13/ 
CH30H 10: 1 (29% yield). Yellow solid, single spot on TLC, 
Rr-0.54 (CHC13/CH30H 10:1), mp 170°-172° C. 1H NMR (CDC13 ) ok, MS (FAB) m/e=588 (90%, M+l), 570 (100%, 
M+l). Anal: calcd. for C3oli41N30 9 , 587; C, 61.31; H, 7.03; 
N, 7.15. Found, C, 60.86; H, 7.29; N, 6.95. 
Example 15 
Z-Leu-Abu-CONH-CH2 CH(OH)C6H4 (4-N(CH3)z). 
This compound was synthesized using 2-amino-1(4-dim-
ethylamino)phenylethanol and purified by column chroma-
tography using AcOEt/hexane 6:1 (23% yield). Yellow solid, 
single spot on TLC, R.rD.41 (AcOEt/hexane 6:1), mp 104° 
C. (dee.). 1H NMR (CDC13 ) ok, MS (FAB) m/e=523 (M+l-
18). Anal: calca. for C29H40N40 6 , 540; C, 64.42; H, 7.45; N, 
Example 10 
Z-Leu-Abu-CONH-(CH2 ) 2C6H4 (4-0CH3). 
25 
10.36. Found, C, 64.27, H, 7.42; N, 10.34. 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 4-methoxyphenethy-
lamine, and purified by column chromatography using 
CHC13'CH30H 50: 1 (50% yield). White solid, single spot 30 
on TLC, Rr-0.46 (CHC13/CH30H 50:1 ), mp 152°-155° C. 
1H NMR(CDC13) ok, MS(FAB) m/e=512(M+ 1). Anal:calcd. 
for C28H37N30 6 , 511; C, 65.73; H, 7.29; N, 8.21. Found, C, 
65.64; H, 7.30; N, 8.19. 
Example 16 
Z-Leu-Abu-CONH-CH2CH(OH)C6F5 • 
This compound was synthesized using 2-amino-1-pen-
tafluorophenylethanol and purified by column chromatog-
raphy using CHC13/CH30H 10:1 (66% yield). White solid, 
single spot on TLC, Rr-0.28 (CHC13'CH30H 10:1), mp 
167°-171° C. 1H NMR (DMSO-d6 ) ok, MS (FAB) m/e=570 
(M+l-18). Anal: calcd. for C27H3aN30 6F5 , 587; C, 55.19; 
35 H, 5.14; N, 7.15. Found, C, 56.13; H, 5.58; N, 7.20. 
Example 11 
Z-Leu-Abu-CONH-CH2C6 H3 (3,5-(0CH3 ) 2 • 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 3,5-dimethoxyphen- 40 
ethylamine, and purified by column chromatography using 
CHC13/CH30H 50: 1 (50% yield). White solid, single spot 
on TLC, Rr-0.46 (CHC13'CH30H 50:1 ), mp 153°-155° C. 
1H NMR (CDC13) ok, MS (FAB) m/e=528 (M+l). Anal: 
calcd. for C28H37N30 7 , 527; C, 63.74; H, 7.07; N, 7.96. 45 
Found, C, 63.66; H, 7.09; N, 7.92. 
Example 12 
Z-Leu-Abu-CONH-CH2CH(OH)Ph. 
This compound was synthesized from 1,3-dithiolane 50 
derivative of Z-Leu-Abu-COOEt and 2-amino-1-phenyle-
thanol by the procedure described in Example 1, and purified 
by column chromatography using CHC13/CH30H 10:1 
(50% yield). White solid, single spot on TLC, R.rD.48 
(CHC13/CH30H 10:1), mp 152°-154° C. 1H NMR (CDC13 ) 55 
ok, MS (FAB) m/e=498 (M+l). Anal: calcd. for 
C27H35N30 6 , 497; C, 65.17; H, 7.09; N, 8.44. Found, C, 




This compound was synthesized using 2-amino-1(3-trif-
luoromethyl)phenylethanol and purified by column chroma-
tography using CHC13/CH30H 10: 1 (72% yield). Dark 
yellow semisolid, single spot on TLC, R.rD.48 (CHC13' 
CH30H 10:1). 1H NMR (CDC13) ok, MS (FAB) m/e=566 
(M+l). Anal: calcd. for C28H34N30 6F3 , 565; C, 59.46; H, 
6.06; N, 7.42. Found, C, 59.12; H, 6.18; N, 7.14. 
Example 18 
Z-Leu-Abu-CONH-CH2CH(OH)C6H4 (3-0Ph). 
This compound was synthesized using 2-amino-1(3-phe-
noxy)phenylethanol and purified by column chromatogra-
phy using CHC13/CH30H 10:1 (67% yield). Yellow oil, 
single spot on TLC, Rr-0.54 (CHC13/CH30H 10:1). 1H 
NMR (CDC13) ok, MS (FAB) rnle=590 (53%, M+l), 572 
(100%, M+l-18). Anal: Calcd. for C33H39N30 7 , 589; C, 





This compound was synthesized using 2-amino-1 ( 4-
methoxy )phenylethanol and purified by column chromatog-
raphy using AcOEt/hexane 3:2 (26% yield). Yellow solid, 
single spot on TLC, R.rD.56 (AcOEt/hexane 1:1 ),mp 
128°-129° C. 1H NMR (CDC13) ok, MS (FAB) m/e=528 
This compound was synthesized using 2-amino-1(4-phe-
noxy)phenylethanol and purified by column chromatogra-
phy using CHC13'CH30H 20:1 (48% yield). Yellow semi-
65 solid, single spot on TLC, R.rD.22 (CHC13/CH30H 20:1), 
mp 55°-60° C. 1H NMR (CDC13) ok, MS (FAB) m/e=590 
(47%, M+l),572 (100%, M+l-18). Anal: calcd. for 
5,514,694 
37 
C33H39N30 7 , 589; C, 67.21; H, 6.66; N, 7.12. Found, C, 
67.30; H, 6.67; N, 7.10. 
Example 20 
Z-Leu-Abu-CONH-CH2CH(OH)C6H4 ( 4-0CH2Ph). 
This compound was synthesized using 2-amino-1 (4-ben-
zyloxy)phenylethanol and purified by column chromatogra-
phy using CHC13/CH30H 20:1 (39% yield). Yellow solid, 
single spot on TLC, R.r=0.40 (CHC13/CH30H 20:1), mp 
59°-62° C. 1H NMR (CDC13 ) ok, MS (FAB) m/e=604 
(M+ 1). Anal: calcd. for C34H41N30 7 , 603; C, 67.64; H, 6.84; 






This compound was synthesized using 2-amino-1-phe-
5 nylethanol and purified by column chromatography using 
CHC13'CH30H 10:1 (46% yield). White solid, single spot 
on TLC, R.r=0.72 (CHC13'CH30H 10:1), mp 164°-166° C. 
1H NMR (CDC13 ) ok, MS (FAB) m/e=560 (M+l). Anal: 
calcd. for C32H37N30 6 , 559; C,68.67; H, 6.66; N, 7.51. 




This compound was synthesized using 2-amino-1(3-(3'-
trifiuoromethyl)phenoxy)phenylethanol and purified by col-
umn chromatography using CHC13'CH30H 30:1 (57% 
yield). Yellow solid, single spot on TLC, R.r=0.40 (CHC13' 20 
CH30H 30:1 ), mp 97°-101° C. 1H NMR (CDC13) ok, MS 
(FAB) m/e=658 (M+l). Anal: calcd. for C34H38N30 7F3 , 
657; C, 62.09; H, 5.82; N, 6.39. Found, C, 62.05; H, 5.84; 
This compound was prepared using 2-amino-1(4-dim-
ethylamino)phenylethanol and purified by column chroma-
tography using CHC13/CH30H 10:1 (22% yield). Yellow 
solid, single spot on TLC, R.r=0.68 (CHC13/CH30H 10:1), 
mp 130° C. (dee.). 1H NMR (CDC13) ok, MS (FAB) 
m/e=603 (35%, M+l), 585 (100%, M+l-18). Anal: calcd. 
for C34H42N4 0 6 , 602; C, 67.75, H, 7.02, N, 9.29. Found, C, 








This compound was synthesized using 2-amino-1(3-(3', 
4'-dichloro)phenoxy)phenylethanol and purified by column 30 
chromatography using CHC13/CH30H 20:1 (55% yield). 
Yellow solid, single spot on TLC, R.r=0.28 (CHC13'CH30H 
20: 1), mp 63°-67° C. 1H NMR (CDC13) ok, MS (FAB) 
This compound was prepared using 2-amino-1-pentafiuo-
rophenylethanol and purified by column chromatography 
using CHC13'CH30H 20:1 (47% yield). White solid, single 
spot on TLC, R.r=0.45 (CHC13/CH30H 20:1), mp 191°-192° 
C. 1H NMR (DMSO-d6 ) ok, MS (FAB) m/e=632 (100%, 
M+l-18).Anal: calcd. forC32H32N30 6F5 , 649; C, 59.16; H, 
4.96; N, 6.46. Found, C, 61.18; H, 5.37; N, 6.68. 
~~~5~, ~~~)N~~-~~-c~~:~:0~,C59~7~1iJ~s.7i' ~:~\~'. 35 Example 29 
Example 23 
Z-Leu-Abu-CONH-CH2CH(OH)C6H3(3,4-(0CH2Phh). 
Z-Leu-Phe-CONH-CH2CH(OH)C6H4 (3-CF3 ). 
This compound was prepared using 2-amino-1(3-trifiuo-
romethyl)phenylethanol and purified by column chromatog-
40 raphy using CHC13'CH30H 20:1 (42% yield). Dark yellow 
semisolid, single spot on TLC, R.r=0.48 (CHC13'CH30H 
10:1). 1H NMR (CDC13 ) ok, MS (FAB) m/e=628 (M+l). 
Anal: calcd. for C33H36N30 6F3 , 627; C, 63.15; H, 5.78; N, 
6.69. Found, C, 63.24; H, 5.82; N, 6.65. 
This compound was synthesized using 2-amino-1(3,4-
dibenzyloxy)phenylethanol and purified by column chroma-
tography using CHC13'CH30H 10:1 (60% yield). White 
solid, single spot on TLC, R_r0.48 (CHC13/CH30H 10:1), 
mp 101°-104° C. 1H NMR (CDC13) ok, MS(FAB) m/e= 
710(M+l). Anal:calcd. for C41H47N30 8 , 709;C, 69.37;H, 45 
6.67;N, 5.92. Found, C, 68.23; H, 6.70; N, 6.08. Example 30 
Z-Leu-Phe-CONH-CH2CH(OH)C6H4 (3-0Ph). Example 24 
Z-Leu-Abu-CONH-CH2CH(OH)-l-C1oH7 • 
This compound was synthesized using 2-amino-1(1-naph-
thyl)phenylethanol and purified by column chromatography 
using AcOEt/hexane 1:1 (15% yield). Pale orange solid, 
single spot on TLC, R_r0.48 (AcOEt/hexane 1: 1 ), mp 
63°-71° C. 1H NMR (CDC13) ok, MS (FAB) m/e=548 
(M+l).Anal: calcd. forC31H37N30 6 , 547; C, 67.99; H, 6.81; 
N, 7.67. Found, C, 67.73; H, 7.03; N, 7.40. 
Example 25 
Z-Leu-Abu-CONH-CH2CH(OH)-2-C1oH7 . 
This compound was synthesized using 2-amino-1 (2-naph-
thyl)phenylethanol and purified by column chromatography 
using AcOEt/hexane 3:2 (17% yield). Orange solid, single 
spot on TLC, R.r=0.39 (AcOEt/hexane 3:1), mp 137°-140° 
C. 1H NMR (CDC13) ok, MS (FAB) m/e=548 (M+l). Anal: 
calcd. for C31H37N30 6 , 547; C, 67.99; H, 6.81; N, 7.67. 
Found, C, 68.15; H, 6.83; N, 7.43. 
This compound was prepared using 2-amino-1 (3-phe-
50 noxy)phenylethanol and purified by column chromatogra-
phy using CHC13'CH30H 20: 1 (50% yield). Yellow semi-
solid, single spot on TLC, R_r0.25 (CHC13/CH30H 20:1). 
1H NMR (CDC13 ) ok, MS (FAB) m/e=652 (M+l). Anal: 
Calcd. for C38H41N30 7 , 651; C, 70.02; H, 6.34; N, 6.44. 
55 Found, C, 69.67; H, 6.60; N, 6.23. 
Example 31 
Z-Leu-Phe-CONH-CH2CH(OH)C6H4(4-0Ph). 
60 This compound was prepared using 2-amino-1(4-phenox-
y)phenylethanol and purified by column chromatography 
using CHC13/CH30H 30:1 (30% yield). Yellow semisolid, 
single spot on TLC, R_r0.20 (CHC13/CH30H 30: 1), mp 
146°-149° C. 1H NMR (CDC13 ) ok, MS (FAB) m/e=652 
65 (25%, M+l), 634 (100%,M+l-18). Anal: calcd. for C38 
H41N30 7 , 651; C, 70.02; H, 6.34; N, 6.44. Found, C, 70.14; 




Z-Leu-Phe-CONH-CH2CH(OH)C6H4 ( 4-0CH2Ph). 
This compound was prepared using 2-amino-1(4-benzy-
loxy)phenylethanol and purified by column chromatography 5 
using CHC13/CH30H 20:1 (49% yield). Yellow solid, single 
spot on TLC, R;=<J.45 (CHC13/CH30H 20:1), mp 133°-134° 
C. 1H NMR (CDC13) ok, MS (FAB) me=666 (M+l). Anal: 
calcd. for C39H43N30 7 , 665; C, 70.35; H, 6.51; N, 6.31. 
Found, C, 69.55; H, 6.46; N, 6.25. 
Example 33 
Z-Leu-Phe-CONH-CH2CH(OH)C6H4-3-0C6H4 (3-CF3 ). 
10 
This compound was prepared using 2-amino-1(3-trifluo-
romethyl)phenoxy)phenylethanol and purified by column 15 
chromatography using CHCliCH30H 20: 1 (52% yield). 
Yellow solid, single spot on TLC, R_r(l.23 (CHC13/CH30H 
20:1), mp 142°-143° C. 1H NMR (CDC13) ok, MS (FAB) 
m/e=720 (M+l). Anal: calcd. for C39H40N30 7F3 , 719; C, 




This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 2-aminomethylpyri-
dine. After reacting overnight at r.t., to the mixture was 
added AcOEt (25 mL) and white precipitate was filtered. 
The filtrate was washed with water (3x10 mL), saturated 
NaCl (2x10 mL) and dried over MgS04 • After evaporation 
of the solvent, chromatography on a silica gel column using 
CHCliCH30H 10: 1 followed by precipitation from AcOEt/ 
hexane afforded a yellow solid (50% yield). 
Single spot on TLC, R_r(l.50 (CHCliCH30H 10: 1), mp 
117°-119° C. 1H NMR (CDC13) ok, MS (FAB) m/e=469 
(M+ 1). Anal: calcd. for C25H32N4 0 5 , 468; C, 64.08; H, 6.88; 
N, 11.96. Found, C, 63.93; H, 6.86; N, 11.85. 
Example 39 
Z-Leu-Abu-CONH-CH2-3-Pyridyl. 
This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Abu-COOEt and 3-aminomethylpyri-
dine by the procedure described in Example 38, and purified 
by column chromatography using CHC13/CH30H 10: 1 (35% yield). Yellow solid, single spot on TLC, R_r(l.54 
(CHC13/CH30H 10:1), mp 122°-123° C. 1H NMR (CDC13) 
ok, MS (FAB) m/e=469 (M+l). Anal: calcd. for 
25 C25H32N40 5 , 468; C, 64.08; H, 6.88; N, 11.96. Found, C, 63.98; H, 6.91; N, 11.97. 
This compound was prepared using 2-amino-1(3-(3',4'-
dichloro)phenoxy)phenylethanol and purified by column 
chromatography using CHCliCH30H 20:1 (41 % yield). 
Yellow solid, single spot on TLC, R_r(l.40 (CHC13/CH30H 
20: 1), mp 136°-137° C. 1H NMR (CDC13) ok, MS (FAB) 
m/e=721 (M+l). Anal: calcd. for C38H39N30 7Cl2, 720; C, 30 





This compound was synthesized using 4-aminomethyl-
pyridine and purified by column chromatography using 
CHCliCH30H 10:1 (45% yield). Yellow solid, single spot 
on TLC, R_r0.55(CHCliCH30H 10:1), mp 124°-126° C. 
1H NMR (CDC13) ok, MS (FAB) m/e=469 (M+l). Anal: 
35 calcd. for C25H32N40 5 , 468; C, 64.08; H, 6.88; N, 11.96. This compound was prepared using 2-amino-1(3,4-diben-
zyloxy)phenylethanol and purified by column chromatogra-
phy using CHC13/CH30H 20:1 (45% yield). Yellow solid, 
single spot on TLC, R_r(l.42(CHCl3/CH30H20:1),mp 
149°-152° C. 1H NMR(CDC13) ok, MS (FAB) m/e=772 (M+l).Anal: calcd. forC46H49N30 8 , 771; C, 71.57; H, 6.39; 4o 
Found, C, 63.88; H, 6.87; N, 11.96. 
Example 41 
Z-Leu-Abu-CONH-(CH2 ) 2 -2-Pyridyl. 
N, 5.44. Found, C, 71.33; H, 6.45; N, 5.41. . 
Example 36 
This compound was synthesized using 2-(2-aminoeth-
yl)pyridine and purified by column chromatography using 
CHC13/CH30H 10:1 (53% yield). Yellow solid, single spot 
on TLC, R_r(l.60 (CHCliCH30H 10:1), mp 128°-130° C. 
Z-Leu-Abu-CONH-CH2-2-Furyl. 45 1H NMR (CDC13 ) ok, MS (FAB) m/e=483 (M+l). Anal: 
This compound was synthesized from 1,3-dithiolane calcd. for C26H34N40 5 , 482; C, 64.71; H, 7.10; N, 11.61. 
derivative ofZ-Leu-Abu-COOEt and 2-furfurylamine by the Found, C, 64.04; H, 7.05; N, 11.49. 
procedure described in Example 1, and purified by column 
chromatography using CHCliCH30H 20:1 (43% yield). 
White solid, single spot on TLC, R_r(l.68 (CHC13/CH30H 50 
10:1), mp 138°-139° C. 1H NMR (CDC13) ok, MS (FAB) 
m/e=458 (M+l). Anal: calcd. for C24H31N30 6 , 457; C, 





This compound was synthesized using 2-tetrahydrofurfu-
rylamine and purified by column chromatography using 
CHC13/CH30H 20:1 (35% yield). Yellow solid, single spot 
This compound was synthesized from protected Z-Leu-
Abu-COOEt and 2(2-aminoethyl)-l-methylpyrrole by the 
procedure described in Example 38, and purified by column 
chromatography using CHCliCH30H 30:1 (16% yield). 55 Orange semisolid, single spot on TLC, R_r(l.34 (CHC13/ 
CH30H 30:1), mp 1.20°-123° C. lHNMR (CDC13 ) ok, MS 
(FAB) m/e=485 (M+ 1). Anal: calcd. for C26H36N40 5 , 484; 




on TLC, R_r(l.59 (CHC13/CH30H 20: 1), mp 126°-128° C. 60 
1H NMR (CDC13) ok, MS (FAB) m/e=462 (M+l). Anal: 
calcd. for C24H35N30 6 , 461; C, 62.45; H, 7.64; N, 9.10. 
Found, C, 62.37; H, 7.63; N, 9.19. This compound was synthesized using 1(3-aminopropy-
65 l)imidazole by the procedure described in Example 38, and 
purified by column chromatography using CHCliCH30H 





R;=Q.33 (CHC13/CH30H 10:1), mp 52°-55° C. 1H NMR 
(CDC13) ok, MS (FAB) m/e=486 (M+l). Anal: calcd. for 
C25H35N50 5 , 485; C, 61.83; H, 7.26; N, 14.42. Found, C, 
60.90; H, 7.21; N, 13.87. 
Example 44 
Z-Leu-Abu-CONH-(CH2) 2-4-Morpholinyl. 
This compound was synthesized using 4-(2-aminoethyl-
)morpholine and purified by column chromatography using 
CHC13'CH30H 10:1 (55% yield). Yellow semisolid, single 
spot on TLC, Rj=0.49 (CHC13'CH30H 10:1),mp 124°-126° 
C. 1H NMR(CDC13) ok, MS (FAB) m/e=491 (M+l). Anal: 
calcd. for C25H38N40 6 , 490; C, 61.15; H, 7.81; N, 11.42. 
Found, C, 61,08; H, 7.86; N, 11.34. 
Example 45 
Z-Leu-Abu-CONH-(CH2h-4-Morpholinyl. 
This compound was synthesized using 4-(3-aminopropy-
l)morpholine and purified by column chromatography using 
CHC13'CH30H 10:1 (42% yield). Yellow semisolid, single 
spot on TLC, R_r0.50 (CHC13/CH30H 10: 1), mp 125°-126° 
5 
42 
for C29H34N40 5, 518; C, 67.16; H, 6.60; N, 10.80. Found, 
C, 67.11; H, 6.61; N, 10.83. 
Example 50 
Z-Leu-Abu-CONH-(CH2h-1-Tetrahydroquinolinyl. 
This compound was synthesized using N-aminopropyltet-
raquinoline and purified by column chromatography using 
CHC13/CH30H 30:1 (40% yield). Oil, single spot on TLC, 
10 R;=Q.26 (CHC13'CH30H 20:1). 1H NMR (CDC13 ) ok, MS 
(FAB) m/e=551 (M+l). Anal: calcd. for C31H42N40 5 , 550; 
C, 67.61; H, 7.69; N, 10.17. Found, C, 67.15; H, 7.42; N, 
10.02. 
15 Example 51 
Z-Leu-Abu-CONH-(CH2h-2-Tetrahydroisoquinolinyl. 
This compound was synthesized using N-aminopropyl-
isotetraquinoline and purified by column chromatography 
20 using CHC13'CH30H 20:1 (20% yield). Yellow semisolid, 
single spot on TLC, R_r0.51 (CHC13/CH30H 20:1 ). 1H 
NMR (CDC13 ) ok, MS (FAB) m/e=551 (M+l). Anal: calcd. 
for C31H42N40 5 , 550; C, 67.61; H, 7.69; N, 10.17. Found, 
C, 67.23; H, 7.32; N, 9.98. 
C. 1H NMR (CDC13) ok, MS (FAB) m/e=505 (M+l). Anal: 
calcd. for C26H4oN40 6 , 504; C, 61.88; H, 7.99; N, 11.10. 
Found, C, 61,69; H, 7.95; N, 11.07. 25 
Exampie 46 
Z-Leu-Abu-CONH-(CH2h- l -Pyrrolidinyl-2-one. 
This compound was prepared from Z-Leu-Abu-COOH 
and 1-(3-aminopropyl)2-pyrrolidinone, and purified by col-
umn chromatography using CHC13'CH30H 10:1 (33% 
yield). White semisolid, single spot on TLC, R;=Q.51 
(CHC13/CH30H 10:1). 1H NMR (CDC13) ok, MS (FAB), 
m/e=503 (M+l). Anal: calcd. for C26H38N40 6, 502; C, 
62.13; H, 7.62; N, 11.14. Found, C, 62.02; H, 7.71; N, 10.52. 
Example 47 
Z-Leu-Abu-CONH-(CHz)2-3-Indolyl. 
This compound was prepared from Z-Leu-Abu-COOH 
and 3-(2-aminoethyl)indole and purified by column chro-
matography using CHC13/CH30H 30:1 (18% yield). White 
semisolid, single spot on TLC, R;=Q.47 (CHC13/CH30H 






This compound was synthesized using 8-aminomethyl-
30 caffeine and purified by column chromatography using 
CHC13'CH30H 20: 1 (30% yield). Yellow solid, single spot 
on TLC, R;=Q.35(CHC13'CH30H 10:1), mp 171°-177° C. 
(dee.). 1H NMR (CDC13 ) ok, MS (FAB) m/e=556 (16%, M+ 
1-28), 471 (100%, M+l-113). Anal: calcd. for C28H37N70 7 , 




This compound was prepared using synthesized 2-ami-
nomethyl-4-methylthiazole and purified by column chroma-
tography using AcOEt/hexane 6:1 (26% yield). Orange 
semisolid, single spot on TLC, R;=Q.40 (AcOEt/hexane 6:1). 
45 1H NMR (CDC13 ) ok, MS (FAB, calcd. for C24H32N40 5S, 
488) m/e=489 (3%, M+l), 376 (100%, M+l-113). 
Example 54 
This compound was prepared from 1,3-dithiolane deriva- 50 
tive of Z-Leu-Abu-COOEt and 2-aminomethylquinoline by 
the procedure described in Example 38, and purified by 
column chromatography using AcOEt/hexane 2:1 (16% 
yield). Yellow solid, single spot on TLC, Rj=0.27 (AcOEt/ 
hexane 2:1), mp 135°-138° C. 1H NMR (CDC13) ok, MS 55 
(FAB) m/e=519 (M+l). Anal: calcd. for C29H34N40 5, 518; 
Z-Leu-Abu-CONH-(CH2)2NH-Biotinyl. 
This compound was prepared front Z-Leu-Abu-COOH 
and biotinylethylenediamine hydrochloride. Biotin (1 g, 4.1 
mmole) was dissolved in 20 mL of DMF at 70° C. and 
cooled to 40° C., CDI (0.97 g, 6 mmole) in 3 mL of DMF 
was then added when a white precipitate appeared. After 
stirring at r.t. for two hours, ethylenediamine (1.34 mL, 20 
mmole) in 10 mL of DMF was added and stirred for another 
3 hours. After evaporating DMF, the semisolid residue was 
dissolved in 50 mL of refluxing methanol and the unreacted 




This compound was prepared using 1-aminomethyliso-
quinoline and purified by column chromatography using 
AcOEt/hexane 2:1 (12% yield). Yellow solid, single spot on 
TLC, R;=Q.34 (AcOEt/hexanel:l),mp 121°-125° C. 1H 
NMR (CDC13 ) ok, MS (FAB)m/e=519(M+l). Anal: calcd. 
60 biotin was removed by filtration. The solution was evapo-
rated to dryness, the residue was washed with CHC13 to 
remove the imidazole, dissolved in 6 mL of water, acidified 
to pH 3.0 with IN HCl, and evaporated to dryness. The 
crude product was crystallized from methanol to give 1.04 
65 g of biotinylethylenediamine hydrochloride (79% yield). 
Long spot on TLC, R;=Q.21 (butanol:AcOH:H20=4:1:1), 
mp 241°-242° C. 1H NMR is consistent with the structure. 
5,514,694 
43 
To a stirred solution of Z-Leu-Abu-COOH (0.6 g, 1.58 
mmol) in DMF (15 mL) was added HOBt (0.22 g, 1.58 
mmol), DCC (0.49 g, 2.38 mmol), and stirring continued for 
2 hours at r.t.(mixture A). To a stirred solution of biotinyl-
ethylenediamine hydrochloride (0.6 g, 1.85 mmol) in DMF 5 
(10 mL) was added TEA (0.28 mL, 2.03 mmol) at 0°-5° C. 
and stirred for 2 hours at r.t.(mixture B). To the stirred 
mixture A was added mixture B and the resulting mixture 
stirred at room temperature for 3 days and then filtered. The 
filtrate was evaporated to get a semisolid which was washed 10 
with H20 (30 mL), lM HCI (30 mL), H20 (30 mL) and dried 
under vacuum. Chromatography on a silica gel column 
using CHC13/CH30H 5:1 afforded a yellow solid (42% 
yield). Long spot on TLC, R_r0.41 (CHC13'CH30H 5: 1), mp 
188°-192° C (dee.). 1H NMR (DMSO-d6) ok, MS (FAB) 
m/e:=647 (M+l). Anal: calcd. for C31H46N60 7S, 646; C, 15 
57.56; H, 7.17; N, 12.99. Found, C, 57.04; H, 7.21; N, 13.29. 
44 
C34H36N40 5, 580; C, 70.32; H, 6.25; N, 9.65. Found, C, 
70.31; H, 6.27; N, 9.63. 
Example 60 
Z-Leu-Phe-CONH--CH2- l -lsoquinoliny l. 
This compound was prepared using 1-aminomethyliso-
quinoline and purified by column chromatography using 
AcOEt/hexane 1:1 (7% yield). Yellow solid, single spot on 
TLC, R,=0.45 (AcOEt/hexane 1:1),mp 169°-173° C. 1H 
NMR (CDC13) ok, MS (FAB) m/e=581 (M+l). Anal: calcd. 
for C34H36N40 5, 580; C, 70.32; H, 6.25; N, 9.65. Found, C, 
70.05; H, 6.29; N, 9.47. 
Example 61 
Z-Leu-Phe-CONH-(CH2)3-1-Tetrahydroquinoliny l. 
This compound was prepared using N-aminopropyltet-
raquinoline and purified by column chromatography using 
CHC13/CH30H 30:1 (40% yield). Yellow solid, single spot 
Example 55 
Z-Leu-Abu-CONH--CH2-3-Pyridyl-N-oxide. 20 on TLC, R_r0.58 (CHC13'CH30H20J),mp 115°-120° C. 1H 
NMR (CDC13) ok, MS (FAB) m/e=613 (M+l). Anal: calcd. 
for C36H44N40 5, 612; C, 70.56; H, 7.24; N, 9.14. Found, C, 
70.46; H, 7.26; N, 9.19. 
This compound was prepared front Z-Leu-Abu-COOH 
and 3-aminomethylpyridine-N-oxide, and purified by col-
umn chromatography using CHC13/CH30H 20:1 (15% 
yield). Yellow oil, long spot on TLC, R_r0.40(CHC13/ 
CH30H5,1). 1H NMR (CDC13) ok, MS(FAB, calcd. for 






This compound was prepared using N-aminopropylisotet-
raquinoline and purified by column chromatography using 
30 
CHC13/CH30H 20: 1 (51 % yield). Yellow solid, single spot 
on TLC, R_r0.62 (CHC13/CH30H 10:1), mp 107°-111° C. 1H NMR (CDC13) ok, MS (FAB) m/e=613 (M+l). Anal: 
calcd. for C36H44N40 5, 612; C, 70.56; H, 7.24; N, 9.14. 
Found, C, 69.61; H, 7.25; N, 9.05. 
This compound was prepared from Z-Leu-Abu-COOH 
and 6-aminomethyluracil and purified by column chroma-
tography using CHC13/CH30H 10: 1 (1.5% yield). Brown 
oil, long spot on TLC, iy=o.28 (CHC13'CH30H 10:1). 1H 
NMR (CDC13) ok, MS (FAB, calcd. for C24H31N50 7, 501) 35 
m/e:=389 (100%, M+l-113). Example 63 
Z-Leu-Phe-CONH-(CH2)2NH-Biotinyl. Example 57 
Z-Leu-Phe-CONH--CH2-2-Pyridyl. 
This compound was prepared from 1,3-dithiolane deriva-
tive of Z-Leu-Phe-COOEt and 2-aminomethylpyridine by 
the procedure described in Example 38, and purified by 
column chromatography using CHC13/CH30H 20:1 (41 % 
yield). Yellow solid, long spot on TLC,_R;=0.40 (CHC13/ 
CH30H 20:1 ), mp 144°-146° C. 1H NMR (CDC13) ok, 
MS(FAB) m/e:=531 (M+l). Anal: calcd. for C30H34N40 5, 




pound was prepared from 1,3-dithiolane derivative of 
Z-Leu-Phe-COOEt and 4-(3-aminopropyl)morpholine, and 
purified by column chromatography using CHC13/CH30H 
10: 1(40% yield). Yellow solid, long spot on TLC, R,=0.55 
(CHC13'CH30H 10:1), mp 155°-156° C. 1H NMR (CDC13) 
ok, MS (FAB) m/e=581 (M+l). Anal: calcd. for 
C31H42N40 6, 566; C, 65.70; H, 7.47; N, 9.89. Found, C, 
65.64; H, 7.49; N, 9.84. 
Example 59 
Z-Leu-Phe-CONH--CH2-2-Quinolinyl. 
This compound was prepared using 2-aminomethylquino-
line and purified by column chromatography using AcOEt/ 
hexane 1:1 (33% yield). Yellow solid, long spot on TLC, 
R,=0.30 (AcOEt/hexane 1: 1), mp 131°-135° C. 1H NMR 
(CDC13) ok, MS (FAB)m/e=581 (M+l). Anal: calcd. for 
This compound was prepared from Z-Leu-Phe-COOH 
and synthesized biotinylethylenediamine hydrochloride by 
40 the procedure described for Example 54, and purified by 
column chromatography using CHC13/CH30H 5:1 (35% 
yield). White solid, long spot on TLC, R,=0.42 (CHC13/ 
CH30H 5:1), mp 204°-206° C. (dee.). 1H NMR (DMSO-~) 
ok, MS (FAB) m/e:=709 (M+l). Anal: calcd. for 
45 C36H48N60 7S, 708; C, 60.99; H, 6.82; N, 11.85. Found, C, 
61.03; H, 6.83; N, 11.77. 
Example 64 
Z-Leu-Nva-CONH--CH2CH(OH)Ph. 50 This compound was synthesized from 1,3-dithiolane 
derivative of Z-Leu-Nva-COOEt and 2-amino-1-phenyle-
thanol by the procedure described in Example 1, and purified 
by column chromatography using CHC13'CH30H 10:1 (54% yield). White solid, single spot on TLC, ~.56 
55 (CHC13'CH30H 10:1), mp 75°-77° C. 1H NMR (CDC13) 
ok, MS (FAB, calcd. for C28H37N30 6, 511) m/e:=512(M+l). 
Example 65 
60 Z-Leu-Nva-CONH--CH2-2-Pyridyl. 
This compound was prepared from 1,3-dithiolane deriva-
tive of Z-Leu-Nva-COOEt and 2-aminomethylpyridine by 
the procedure described in Example 38, and purified by 
column chromatography using CHC13/CH30H 10: 1 (50% 
65 yield). Yellow solid, long spot on TLC, R_F0.55 (CHC13' 
CH30H 10:1), mp 65°-70° C. 1H NMR (CDC13) ok, MS 






ok, MS (FAB) m/e=377 (M+l). Anal: calcd. for 
C19H28N40 4, 376; C, 60.58; H, 7.49; N, 14.92. Found, C, 
60.05; H, 7.51; N, 14.58. 
Example 71 
2-Pyrazinyl-CO-Leu-Abu-CONHEt. 
This compound was synthesized using 2-pyrazinecar-
boxylic acid and purified by column chromatography using 
This compound was prepared from 1,3-dithiolane deriva-
tive of Z-Leu-Nva-COOEt and 4-(3-aminopropyl)morpho- 5 
line, and purified by column chromatography using CHC13/ 
CH30H 10:1(37% yield). Yellow solid, long spot on TLC, 
R.r=0.23 (CHC13'CH30H 10:1), mp 108°-110° C. 1H NMR 
(CDC13) ok, MS (FAB, calcd. for C27H42N40 6, 518) m/e= 
519 (M+l). 10 CHCVCH30H 10:1 (18% yield). Yellow solid, single spot 
on TLC, R.r=0.33 (CHC13'CH30H 10:1), mp 51°-56° C. 1H 
NMR (CDC13) ok, MS (FAB) m/e=378 (M+l). Anal: calcd. 
for C18H27N50 4377; C, 57.29; H, 7.16; N, 18.56. Found, C, 
56.74; H, 7.28; N, 18.32. 
Example 67 
CH30CO(CH2)2CO-Leu-Abu-CONHEt. 
To a solid Z-Leu-Abu-CONHEt (1 g, 2.47 mmol) was 
added a solution of hydrogen bromide in acetic acid (30 wt 15 
%, 1.52 mL, 7.40 mmol) at r.t. The mixture was vigorously 
stirred for 1 hour during which time all of the ketoamide 
went into solution. The reaction was quenched with Et20 
(30 mL) then separated. The semisolid was triturated and 
washed successively with E~O (5x30 mL). After removing 20 
solvent, the residue was dried under vacuum, leaving a very 
hygroscopic solid. 1H NMR (CDC13) showed loss of Z 
group. The yield was 70-80%. 
To a stirred solution of mono-methylsuccinate (0.28 g, 
2.13 mmol) in DMF (10 mL) was added DCC (0.44 g, 2.13 25 
mmol) and HOBt (0.29 g, 2.13 mmol). The mixture was 
stirred for 2 hours at r.t.(mixture A). To a stirred solution of 
Leu-Abu-CONHEt. HBr (0.5 g, 1.42 mmol) in DMF (5 mL) 
was added TEA (0.2 mL, 1.42 mmol) at 0°-5° C. and stirred 
for 30 min (mixture B). To the stirred mixture B was added 30 
mixture A at 0°-5° C. and the reaction was stirred overnight 
at r.t. After evaporation of the solvent, AcOEt (40 mL) was 
added, the precipitate was filtered, and the filtrate washed 
with 0.25 N HC1 (10 mL), H20 (20 mL), 10% Na2C03 
(3x20 mL), H20 (20 mL), satd. NaCl (2x20 mL), dried over 35 
MgS04, and concentrated. Chromatography on a silica gel 
column with CHC13'CH30H 10: 1 afforded a yellow semi-
solid (42% yield). Single spot on TLC, R.r=0.43 (CHC13/ 
CH30H 10:1). 1H NMR (CDC13) ok, MS (FAB, calcd. for 
C18H31N30 6, 385) m/e=386 (M+l). . 40 
Example 72 
2-Quinoliny 1-CO-Leu-Abu-CONHEt. 
This compound was synthesized using quinaldic acid and 
purified by column chromatography using AcOEt/hexane 
1:1 (45% yield). Orange solid, single spot on TLC, Rj=0.48 
(AcOEt/hexane 1:1), mp 56°-59° C. 1H NMR (CDC13) ok, 
MS (FAB) m/e=427 (M+l). Anal: calcd. for C23H3oN404, 




This compound was synthesized using 1-isoquinoline 
carboxylic acid and purified by column chromatography 
using AcOEt/hexane 1:1 (46% yield). Red solid, single spot 
on TLC, R.r=0.47 (AcOEt/hexane 1:1),mp 104°-106° C. 1H 
NMR (CDC13) ok, MS (FAB) m/e=427 (M+l). Anal: calcd. 
for C23H3oN40 4, 426; C, 64.79; H, 7.09; N, 13.13. Found, 
C, 65.00; H, 7.31; N, 12.96. 
Example 74 
4-Morpholinyl-CO-Leu-Abu-CONHEt. 
This compound was synthesized from 4-morpholinecar-
bonyl chloride (1 mmol), Leu-AbuCONH-Et.HBr (1 mmol) 
and TEA (2.5 mmol), and purified by column chromatog-
raphy using CHC13/CH30H 10:1 (33% yield). Yellow oil, 
single spot on TLC, R.r=0.45 (CHC13/CH30H 10:1). 1H 
Example 68 
2-Furyl-CO-Leu-Abu-CONHEt. 
This compound was synthesized using 2-furoic acid by 45 NMR (CDC13) ok, MS (FAB, calcd. for C18H32N40 5 , 384) 
m/e=385 (M+l). the procedure described for compound 67 and purified by 
column chromatography using CHC13/CH30H 30: 1 (39% 
yield). Yellow solid, single spot on TLC, Rt=0.51 (CHC13' 
CH30H10:1), mp 58°-59° C. 1H NMR (CDC13) ok, MS 
(FAB) m/e=366(M+l). Anal:calcd. for C18H27N30 5, 365;C, 50 
59.16;H, 7.44; N, 11.50. Found, C, 58.12; H, 7.53; N, 11.64. 
Example 69 
2-Tetrahydrofuryl-CO-Leu-Abu-CONHEt. 
This compound was synthesized using 2-tetrahydrofuroic 
acid and purified by column chromatography using CHC13' 
CH30H 30:1 (41% yield). Yellow oil, single spot on TLC, 
R.r=0.54 (CHC13/CH30H 10:1). 1H NMR (CDC13) ok, MS 
(FAB, calcd. for C18H31N30 5 , 369) m/e=370 (M+l). 
Example 70 
3-Pyridyl-CO-Leu-Abu-CONHEt. 
This compound was synthesized using nicotinic acid and 
purified by column chromatography using CHC13'CH30H 
10:1 (49% yield). Yellow solid, single spot on TLC, R.r=0.56 
(CHC13/CH30H 10:1), mp 57°-61° C. 1H NMR (CDC13) 
Example 75 
Ph(CH2hCO-Leu-Abu-CONHEt. 
This compound was synthesized from 1,3-dithiolane 
derivative of Ph(CH2hCO-Leu-Abu-COOEt and EtNH2, 
and purified by column chromatography using CHC13/ 
CH30H 30: 1 (72% yield). Yellow solid, single spot on TLC, 
R.r=0.23(CHC13'CH30H 30:1),mp 134°-136° C. 1H NMR 
55 (CDC13) ok, MS (FAB) m/e=404 (M+l). Anal: calcd. for 
C22H33N30 4403; C, 65.48; H, 8.24; N, 9.60. Found, C, 




This compound was synthesized from 1,3-dithiolane 
derivative of 1-C1oH7CO-Leu-Abu-COOEt and EtNH2, and 
purified by column chromatography using CHC13'CH30H 
65 30:1 (67% yield). Yellow solid, single spot on TLC, R.r=0.47 
(CHCl3/CH30H 30: 1), mp 201°-203° c. 1H NMR (CDCl3) 
ok, MS (FAB) m/e=440 (M+l). Anal: calcd. for 
5,514,694 
47 
C25H33N30 4 , 439; C, 68.31; H, 7.57; N, 9.56. Found, C, 




This compound was synthesized from 1,3-dithiolane 
derivative of Ph2CHCO-Leu-Abu-COOEt and EtNH2 , and 
purified by column chromatography using CHC13'CH30H 
10:1 (24% yield). Yellow solid, single spot on TLC, R,r=0.40 
10 (CHC13/CH30H 10: 1), mp 78°-83° C. 1H NMR (CDC13 ) 
ok, MS (FAB) m/e=467 (M+l). Anal: calcd. for 
C27H35N30 4 , 466; C, 69.65; H, 7.58; N, 9.02. Found, C, 
70.04; H, 7.72; N, 8.72. 
48 
Yellow solid, single spot on TLC, R,r=0.33 (AcOET/CH30H 
9:1), mp 160°-162° C. 1H NMR (CDC13) ok, MS (FAB) 
m/e==591 (M+l). Anal: calcd. for C36H38N40 4 , 590; C, 
73.20; H, 6.48; N, 9.48. Found, C, 69.91; H, 6.29; N, 8.98. 
Example 83 
Ph2CHCO-Leu-Phe-CONH-(CH2h-4-Morpholinyl. 
This compound was synthesized from 1,3-dithiolane 
derivative of Ph2CHCO-Leu-Phe-COOEt and N-aminopro-
pylmorpholine, and purified by column chromatography 
using AcOEt followed by crystallization from AcOEt/ether 
(20% yield). Yellow solid, single spot on TLC, Rf =0.45 
(AcOET/CH30H 9:1), mp 158°-160° C. 1H NMR (CDC13 ) 
ok, MS (FAB) m/e=627 (M+l). Anal: calcd. for 
Example 78 
Ph2CHCO-Leu-Abu-CONH-CH2CH(OH)Ph. 
15 C37H46N40 5 , 626; C, 70.90; H, 7.40; N, 8.94. Found, C, 
70.05; H, 7.43; N, 8.68. 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 
spirit of the invention or the scope of the subjoined claims 
20 and their equivalents. 
This compound was synthesized from 1,3-dithiolane 
derivative of Ph2CHCO-Leu-Abu-C00Et and 2-amino-1-
phenylethanol, and purified by column chromatography 
using CHC13 followed by CHC13'CH30H 30:1 (30% yield.). 
Yellow solid, single spot on TLC, R,r=0.40 (AcOEt/hexane 
1:1), mp 178°-180° C. 1H NMR (CDC13) ok, MS (FAB) 
m/e==558 (M+l). Anal: calcd. for C33H39N30 5 , 557; C, 
71.07; H, 7.05; N, 7.53. Found, C, 70.93; H, 7.10; N, 7.46. 25 
Example 79 
Ph2CHCO-Leu-Abu-CONH-2-CH2-Pyridyl. 
This compound was prepared from 1,3-dithiolane deriva-
30 tive of Ph2CHCO-Leu-Abu-COOEt and 2-aminomethylpy-
ridine, and purified by column chromatography using CHC13 
following by CHC13/Ac0Et 7:3 (9% yield), mp 161-163. 
Yellow solid, single spot on TLC, R,r=0.30 (CHCl3'CH3QH 
10:1). 1H NMR (CDC13) ok, MS (FAB) m/e==529 (M+l). 35 Anal: calcd. for C31H36N40 4 , 528; C, 70.43; H, 6.86; N, 
10.60. Found, C, 70.42; H, 6.91; N, 10.47. 
Example 80 
Ph2CHCO-Leu-Abu-CONH-N-(CH2h-Morpholinyl. 40 
This compound was prepared from 1,3-dithiolane deriva-
tive of Ph2CHCO-Leu-Abu-COOEt and N-aminopropyl-
morpholine, and purified by column chromatography using 
CHC13 followed by CHC13'Ac0Et 7:3 (25% yield), mp 
170--174. Yellow solid, single spot on TLC, R,r=0.25 45 
(CHC13'CH30H 10:1). 1H NMR (CDC13 ) ok, MS (FAB) 
m/e==565 (M+l). Anal: calcd. for C32H44N40 5 , 564; C, 




This compound was prepared from 1,3-dithiolane deriva-
tive of Ph2CHCO-Leu-Phe-COOEt and 2-amino-1-phenyle-
thanol, and purified by crystallization from CHC13/ether 55 (16% yield). Yellow solid, single spot on TLC, R,r=0.41 
(Ac0ET/CH30H 9: 1), mp 192°-196° C. 1H NMR (CDC13 ) 
ok, MS (FAB) m/e=620 (M+l). Anal: calcd. for 
C38H41N30 5 , 619; C, 73.64; H, 6.67; N, 6.78. Found, C, 




This compound was synthesized from 1,3-dithiolane 
derivative of Ph2CHCO-Leu-Phe-COOEt and 2-aminom- 65 
ethylpyridine, and purified by column chromatography 
using CHC13 following by CHC13'Ac0Et 9:1 (9% yield). 
What is claimed is: 
1. A compound of the formula: 
Y-CO-AA2-AA1-CO-NH-X 
or a pharmaceutically acceptable salt, wherein 
Y is selected from the group consisting of C1_4 alkyl 
monosubstituted with phenyl, C1_4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxy dis-
ubstituted with phenyl, ArCH20-, ArO-, 
ArCH2NH-, ArNH-, M1-(CH2)q-, and 
M 2-(CH2)q-O-; 
wherein Ar is selected from the group consisting of 
phenyl, phenyl monosubstituted with J, phenyl disub-
stituted with J, 1-naphthyl, 1-naphthyl monosubstituted 
with J, 2-naphthyl, and 2-naphthyl monosubstituted 
with J; 
J is selected from the group consisting of halogen, OH, 
CN, N02 , NH2, COOH, C02Me, C02Et, CF3 , C1_4 
alkoxy, C1_4 alkylamine, C2_8 dialkylamine, C1_4 per-
fluoroalkyl, and -N(CH2CH2)20; 
M1 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 
2-pyrazinyl, 2-quinolinyl, 1-tetrahydroquinolinyl, 
1-isoquinolinyl, 2 -tetrahydroisoquinolinyl, and 
-N(CH2CH2)20; 
q=0--2; 
M2 is selected from the group consisting of 2-furyl, 
2-tetrahydrofuryl, 2-pyridyl, 2-pyrazinyl, 2-quinolinyl, 
2-tetrahydroquinolinyl, 1-isoquinolinyl, and 1-tetrahy-
droisoquinoliny l; 
AA 2 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, valine, leucine, 
isoleucine, proline, histidine, methionine, methionine 
sulfoxide, phenylalanine, serine, threonine, phenylgly-
cine, norleucine, norvaline, alpha-aminobutyric acid, 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-cyclohexyl)-COOH, NH2-CH(CH2-
cyclopentyl)-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH2-CH(CH2 -cyclopropyl)COOH, 5,5,5-
trifluoroleucine, and hexafluoroleucine; 
5,514,694 
49 
AA 1 is an amino acid with the L configuration, D con-
figuration, or DL configuration at the a-carbon selected 
from the group consisting of alanine, 4-chloropheny-
lalanine, valine, leucine, isoleucine, proline, histidine, 
methionine, methionine sulfoxide, phenylalanine, argi- 5 
nine, lysine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutanrine, aspartic acid, 
glutarnic acid, phenylglycine, norleucine, norvaline, 
alpha-arninobutyric acid, 0-methylserine, O-eth-
10 ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEti)-COOH, alpha-arni-
noheptanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH, NH2-CH(CH2-




X is selected from the group consisting of 
a)-CH2CH(OH)-R1 and 
b) -(CH2)n-R3 ; 
R 1 is selected from the group consisting of phenyl, phenyl 
monosubstituted with J, phenyl disubstituted with J, 








1-naphthyl, 1-naphthyl monosubstituted with J, 40 
1-naphthyl disubstituted with J, 2-naphthyl, 2-naphthyl 
monosubstituted with J, 2-naphthyl disubstituted with 
J, 2-pyridyl, 2-quinolinyl, and 1-isoquinolinyl; 
R2 represents C1_4 alkyl, C1_4 alkyl substituted with 
phenyl, phenyl, and phenyl substituted with J; 
n=l-3; 
45 
R3 is selected from the group consisting of2-furyl, 2-furyl 
monosubstituted with J, 2-pyridyl, 2-pyridyl monosub-
stituted with J, 3-pyridyl, 3-pyridyl monosubstituted 50 
with J, 4-pyridyl, 4-pyridyl monosubstituted with J, 
2-quinolinyl, 2-quinolinyl monosubstituted with J, 
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2. A compound of the formula: 
Y--CO-AA2-AA1--CO-NH-X 
or a pharmaceutically acceptable salt as claimed in claim 1, 
wherein 
y is selected from the group consisting of cl-4 alkyl 
monosubstituted with phenyl, C14 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, cl-4 alkoxy dis-
ubstituted with phenyl, ArCH20-, ArO-, 
ArCH2NH-, and ArNH-; 
X is -CH2CH(OH)-R 1 • 
3. A compound of the formula: 
Y-CO-AA2-AA1--CO-NH-X 
(>___ co 
55 or a pharmaceutically acceptable salt as claimed in claim 2, 
wherein 
0 N ' I 
CO rY~ N-.~ 
60 
65 
Y is selected from the group consisting of PhCH2CH2-, 
Ph2CH-, 1-naphthyl-CH2-, 2-naphthyl-CH2-, 
PhCH20-, Ph2CHO-, 1-naphthyl-CH20-, 2-naph-
thyl-CH20-, PhCH2NH-, 1-naphthyl-CH2NH-, 
and 2-naphthyl-CH2NH-; 
AA 2 is selected from the group consisting of leucine, 
isoleucine, valine, and methionine; 
AA 1 is selected from the group consisting of phenylala-
nine, alpha-arninobutyric acid, norleucine, norvaline, 
methionine, and 4-chlorophenylalanine; 
5,514,694 
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4. A compound of the formula: 
Y-CO-AA2-AA1-CO-NH-X 













Y is selected from the group consisting of C1_4 alkyl 60 
monosubstituted with phenyl, C1_4 alkyl disubstituted 
with phenyl, C1_4 alkyl monosubstituted with 1-naph-
thyl, cl-4 alkyl monosubstituted with 2-naphthyl, cl-4 
alkoxy monosubstituted with phenyl, C1_4 alkoxy dis-
ubstituted with phenyl, ArCH20-, ArO-, 65 
ArCH2NH-, and ArNH-; Xis -(CH2)n-R3 . 
5. A compound of the formula: 
52 
Y-CO-AA2-AA1-CO-NH-X 
or a pharmaceutically acceptable salt as claimed in claim 4, 
wherein 
Y is selected from the group consisting of PhCH2CH2-, 
Ph2CH-, 1-naphthyl-CH2-, 2-naphthyl-CH2-, 
PhCH20-, Ph2CHO-, 1-naphthyl-CH20-, 2 -naph-
thyl-CH20-, PhCH2NH-, l-naphthyl-CH2NH-, 
and 2-naphthyl-CH2NH-; 
AA 2 is selected from the group consisting of leucine, 
isoleucine, valine, and methionine; 
AA 1 is selected from the group consisting of phenylala-
nine, alpha-aminobutyric acid, norleucine, norvaline, 
methionine, and 4-chlorophenylalanine; 
R3 is selected from the group consisting of 2-furyl, 
2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolinyl, 1-iso-
quinolinyl, 
CXJ N ' (>_ 0 I 
0[~~ 
N , N , N 0, 
I I I 
Me 
0 Me 
Me ~I ~ JL~>- -4 >-Me 
0 N , N , 
I 
Me 




orha p~armaceutically acceptable salt as claimed in clm"m 1 
w erem , 
Y is M 1-(CH) _. 2 q , 
Xis -CH2CH(OH)-R1. 




orha p. armaceutically acceptable salt as claimed in clm"m 6 
w erem , 
AA2 · iso!:u~~~:ct~~:~manthd emegthro?p . consisting of leucine, 
' , 10mne· 
AA 1 is selected fr th '. . 
15 
nine al h .om e !l1"ou~ consist:mg of phenylala-
methl ~ a-ammobutync acid, norleucine, norvaline 
onme, and 4-chlorophenylalanine· , 
R 1 is selected fro th . : 1-naphth 1 2 . m e group consistmg of phenyl 















8. A compound of the formula: 
Y---CO-AA2-AA'---CO-NH-X 
or a p~armaceutically acceptable salt as claimed in clai 1 
wherem m , 
Y is M1-(CH) _. 2 q , 
Xis -(CHi)n-R3. 
9. A compound of the formula: 
Y-CO-AA2-AA'---CO-NH-X 
or a p~armaceutically acceptable salt as claimed in cl . 8 
wherem mm , 
AA 2 is selected from the . . 
. 1 . group consisting of leucine 
iso eucme, valine, and methionine· ' 
AA1. 1 , 
. is se ected ~om the group consisting of phenylala-
:ne,. al~ha-ammobutyric acid, norleucine, norvaline 
ethiomne, and 4-chlorophenylalanine· , 
R3 . , 2~s s~lected fro~ the group consisting of 2-furyl, 
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10. A compound of the formula: 
Y-CO-AA2-AA 1-CO-NH-X 
or a pharmaceutically acceptable salt as claimed in claim 1, 
wherein 
Y is M 2-(CH2)q-O-; 
Xis -CH2CH(OH)-R1 • 
11. A compound of the formula: 
Y-CO-AA2-AA1-CO-NH-X 







AA 2 is selected from the group consisting of leucine, 
isoleucine, valine, and methionine; 
AA1 is selected from the group consisting of phenylala-
nine, alpha-aminobutyric acid, norleucine, norvaline, 35 
methionine, and 4-chlorophenylalanine; 





















12. A compound of the formula: 
Y-CO-AA2-AA1-CO-NH-X 
or a pharmaceutically acceptable salt as claimed in claim 1, 
wherein 
Y is M2-(CH2)q-O-; 
Xis -(CH2)n-R3 . 
13. A compound of the formula: 
Y-C0-AA2-AA1-CO-NH-X 
or a pharmaceutically acceptable salt as claimed in claim 12, 
wherein 
AA 2 is selected from the group consisting of leucine, 
isoleucine, valine, and methionine; 
AA1 is selected from the group consisting of phenylala-
nine, alpha-aminobutyric acid, norleucine, norvaline, 
methionine, and 4-chlorophenylalanine; 
R3 is selected from the group consisting of 2-furyl, 
2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolinyl, 1-iso-
quinolinyl, 
('>- 00 
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14. A compound selected from the group consisting of: 
(a) Z-Leu-Abu-CONH-(CH2)zOH, (b) Z-Leu-Abu-CONH-(CH2) 50H, (c) Z-Leu-Abu-CONH-(CH2)zO(CHz)20H, 
(d) Z-Leu-Abu-CONH-CH2CH(OCH3)z, 
(e) Z-Leu-Abu-CONH-CH2CH(OCzH5)z, (f) Z-Leu-Abu-CONH-CH2-C6H8[1,3,3-(CH3h-5-0H], (g) Z-Leu-Abu-CONH-(CH2)zC6H4 (4-0H), (h) Z-Leu-Abu-CONH-(CH2 )zC6H4 (2-0CH3), (i) Z-Leu-Abu-CONH-(CH2)zC6Hi3-0CH3), 
(j) Z-Leu-Abu-CONH-(CH2)zC6Hi 4-0CH3), 
(k) Z-Leu-Abu-CONH-CH2C6H3[3,5-(0CH3)z], 
(1) Z-Leu-Abu-CONH-CH2CH(OH)Ph, 
(m) Z-Leu-Abu-CONH-CH2CH(OH)C6H4 ( 4-0CH3), 
(n) Z-Leu-Abu-CONH-CH2CH(OH)C6H2 [2,4,6-
(0CH3h], 
(o) Z-Leu-Abu-CONH-CH2CH(OH)C6H4 [4-N(CH3)z], 
(p) Z-Leu-Abu-CONH-CH2CH(OH)C6F5 , 
(q) Z-Leu-Abu-CONH-CH2CH(OH)C6H4 (3-CF3), 
(r) Z-Leu-Abu-CONH-CH2CH(OH)C6H4(3-0Ph), 













(bb) Z-Leu-Phe-CONH-CH2CH(OH)C6F5 , 
(cc) Z-Leu-Phe-CONH-CH2CH(OH)C6H4(3-CF3), 
(dd) Z-Leu-Phe-CONH-CH2CH(OH)C6Hi3-0Ph), 
5 (ee) Z-Leu-Phe-CONH-CH2CH(OH)C6Hi4-0Ph), 
(fl) Z-Leu-Phe-CONH-CH2CH(OH)C6Hi 4-0CH2Ph), 




























35 (eee) Z-Leu-Abu-CONH-CH2-3-pyridyl-N-oxide, 
(fff) Z-Leu-Abu-CONH-CH2-6-uracil, 
(ggg) Z-Leu-Phe-CONH-CH2-2-pyridy 1, 
(hhh) Z-Leu-Phe-CONH-(CH2k4-morpholinyl, 
(iii) Z-Leu-Phe-CONH-CH2-2-quinolinyl, 
40 (jjj) Z-Leu-Phe-CONH-CH2-l-isoquinolinyl, 
(kkk) Z-Leu-Phe-CONH-(CH2h-1-tetrahydroquinoliny I, 
(lll) Z-Leu-Phe-CONH-(CH2h-2-tetrahydroisoquinoliny 1, 
(mmm) Z-Leu-Phe-CONH-CH2)2-NH-biotinyl, 
(nnn) Z-Leu-Nva-CONH-CH2CH(OH)Ph, 




(sss) 2-tetrahydrofury 1-CO-Leu-Abu-CONHEt, 
50 (ttt) 3-pyridyl-CO-Leu-Abu-CONHEt, 
(uuu) 2-pyrazyl-CO-Leu-Abu-CONHEt, 
( vvv) 2-quinolinyl-CO-Leu-Abu-CONHEt, 
(www) 1-isoquinolinyl-CO-Leu-Abu-CONHEt, 
(xxx) 4-morpholinyl-CO-Leu-Abu-CONHEt, 








(ffff) Ph2CHCO-Leu-Phe-CONH-CH2-2-pyridyl, and 
(gggg) Ph2CHCO-Leu-Phe-CONH-(CH2)3-4-morpholi-
65 nyl. 
* * * * * 
